Mesenchymal stromal cell exosome-treated monocytes and uses thereof
Mesenchymal stem cell exosomes modulate monocyte phenotype to treat idiopathic pulmonary fibrosis by converting pro-inflammatory monocytes to regulatory monocytes, effectively reducing fibrosis and restoring lung structure.
Patent Information
- Application Number
- JP2024058604
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-05-09
- Filing Date
- 2024-04-01
- Publication Date
- 2024-11-26
AI Technical Summary
Idiopathic pulmonary fibrosis (IPF) is a chronic respiratory disease with a lack of complete understanding of its mechanisms, leading to limited effective treatments, and existing mesenchymal stem cell (MSC) therapies face challenges such as adverse immune responses and potential fibroblast differentiation.
Administration of mesenchymal stem cell exosomes (MEx) modulates monocyte phenotype in bone marrow, converting pro-inflammatory monocytes to regulatory monocytes, reducing inflammation and apoptosis, and is administered intravenously to treat pulmonary fibrosis.
MEx treatment significantly reduces pulmonary fibrosis by altering monocyte phenotype, preventing collagen deposition and restoring lung structure, even when administered during or after the inflammatory phase.
Smart Images

Figure 2024163978000001 
Figure 2024163978000002 
Figure 2024163978000003
Abstract
Description
[Technical field]
[0001] Related Applications This application claims the benefit under 35 USC § 119(e) of U.S. Provisional Application No. 62 / 669,324, filed May 9, 2018, and entitled “Mesenchymal Stromal Cell Exosome-Treated Monocytes and Uses Thereof,” the entire contents of which are incorporated herein by reference. [Background technology]
[0002] background Idiopathic pulmonary fibrosis (IPF) is a chronic progressive respiratory disease with a prevalence of 0.5 to 27.9 per 100,000 person-years. A lack of complete understanding of the mechanisms underlying the disease may have contributed to the lack of successful treatments. Despite two newly approved drugs, IPF remains fatal with a 5-year survival rate of less than 10%. Summary of the Invention
[0003] overview Herein, it was shown that a single intravenous (IV) dose of mesenchymal stem cell (MSC) exosomes reversed bleomycin-induced pulmonary fibrosis, at least in part, through modulation of monocyte phenotype in bone marrow and reduction of alveolar epithelial cell (AEC) apoptosis. Furthermore, monocytes treated with MSC exosomes were therapeutically effective against pulmonary fibrosis when administered to subjects with the disease.
[0004] Accordingly, provided herein, in some aspects, is a method of modulating monocyte phenotype, the method comprising contacting monocytes with isolated mesenchymal stem cell (MSC) exosomes. In some embodiments, the monocytes are from bone marrow.
[0005] In some embodiments, the isolated MSC exosomes are isolated from MSC conditioned medium. In some embodiments, the MSCs are from Wharton's jelly, bone marrow, or adipose tissue. In some embodiments, the isolated MSC exosomes are substantially free of protein contaminants. In some embodiments, the isolated MSC exosomes have a diameter of about 50-150 nm.
[0006] In some embodiments, the contacting is in vitro. In some embodiments, the contacting is ex vivo. In some embodiments, the contacting is in vivo. In some embodiments, the contacting is for at least 2 hours.
[0007] In some embodiments, the monocytes are pro-inflammatory before contact with the isolated MSC exosomes and are regulatory after contact with the isolated MSC exosomes.
[0008] Another aspect of the present disclosure provides a method of treating a fibrotic or autoimmune disease, comprising administering an effective amount of monocytes to a subject in need thereof, wherein the monocytes are treated with isolated mesenchymal stem cell (MSC) exosomes prior to administration.
[0009] In some embodiments, the method further comprises isolating monocytes before treating the monocytes with MSC exosomes. In some embodiments, the monocytes are isolated from the subject. In some embodiments, the monocytes are isolated from the bone marrow of the subject.
[0010] In some embodiments, the monocytes are treated with MSC exosomes for at least 2 hours before being administered to a subject. In some embodiments, the monocytes are administered systemically. In some embodiments, the monocytes are administered via intravenous infusion. In some embodiments, the monocytes are administered intratracheally or intranasally. In some embodiments, the monocytes are administered once to a subject. In some embodiments, the monocytes are administered multiple times to a subject.
[0011] In some embodiments, the method further comprises administering to the subject an effective amount of a second agent. In some embodiments, the second agent is isolated MCS exosomes. In some embodiments, the second agent is nintedanib, pirfenidone, an antifibrotic agent, an immunosuppressant, and / or an anti-inflammatory agent.
[0012] In some embodiments, the fibrotic disease is selected from the group consisting of: systemic sclerosis; liver fibrosis, cardiac fibrosis, renal fibrosis, and bone marrow fibrosis. In some embodiments, the fibrotic disease is pulmonary fibrosis. In some embodiments, the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). In some embodiments, the monocytes reduce inflammation associated with the fibrotic disease. In some embodiments, the monocytes reduce apoptosis associated with the fibrotic disease.
[0013] In some embodiments, the subject is a mammal. In some embodiments, the subject is a human subject. In some embodiments, the human is a newborn, an infant, or an adult. In some embodiments, the human subject is less than 4 weeks old. In some embodiments, the human subject is between 4 weeks and 3 years old. In some embodiments, the human subject is between 3 and 18 years old. In some embodiments, the human subject is an adult.
[0014] In some embodiments, the human subject is born at low birth weight. In some embodiments, the human subject is born before 37 weeks gestation. In some embodiments, the human subject is born before 26 weeks gestation.
[0015] In some embodiments, the subject is a rodent. In some embodiments, the rodent is a mouse or a rat.
[0016] In some embodiments, the monocytes are pro-inflammatory before treatment with the isolated MSC exosomes and are regulatory after treatment with the isolated MSC exosomes.
[0017] Another aspect of the present disclosure provides monocytes treated with isolated mesenchymal stem cell (MSC) exosomes. In some embodiments, the monocytes are from bone marrow. In some embodiments, the isolated MSC exosomes are isolated from MSC conditioned medium. In some embodiments, the MSCs are from Wharton's jelly, bone marrow, or adipose tissue. In some embodiments, the monocytes are pro-inflammatory before being treated with isolated MSC exosomes and are regulatory after being treated with isolated MSC exosomes.
[0018] Also provided are compositions comprising the monocytes described herein. In some embodiments, the composition further comprises a second agent. In some embodiments, the composition is a pharmaceutical composition. In some embodiments, the composition further comprises a pharma- ceutically acceptable carrier.
[0019] Further provided herein is the use of the monocytes or compositions comprising monocytes described herein for treating a fibrotic or autoimmune disease.
[0020] The monocytes or compositions comprising monocytes described herein may also be used in the manufacture of a medicament for treating a fibrotic or autoimmune disease.
[0021] The above summary is intended to illustrate, in a non-limiting manner, some of the aspects, advantages, features, and uses of the technology disclosed herein. Other aspects, advantages, features, and uses of the technology disclosed herein will become apparent from the detailed description, drawings, examples, and claims. [Brief description of the drawings]
[0022] [Figure 1A-1B] Figure 1A shows that MEx treatment at the onset of inflammation prevents fibrosis. Figure 1B shows that MEx treatment at the onset of inflammation prevents fibrosis. [Fig. 1C-1D]Figure 1C shows that MEx treatment at the onset of inflammation prevents fibrosis. Figure 1D shows that MEx treatment at the onset of inflammation prevents fibrosis.
[0023] [Figure 2A-2C] Figure 2A shows that MEx regulates alveolar macrophage phenotype and blunted inflammation. Figure 2B shows that MEx regulates alveolar macrophage phenotype and blunted inflammation. Figure 2C shows that MEx regulates alveolar macrophage phenotype and blunted inflammation. [Fig. 2D-2E] Figure 2D shows that MEx regulates alveolar macrophage phenotype and blunted inflammation.Figure 2E shows that MEx regulates alveolar macrophage phenotype and blunted inflammation.
[0024] [Figure 3A-3D] Figure 3A shows that MEx regulates monocyte and macrophage phenotype at the systemic level. Figure 3B shows that MEx regulates monocyte and macrophage phenotype at the systemic level. Figure 3C shows that MEx regulates monocyte and macrophage phenotype at the systemic level. Figure 3D shows that MEx regulates monocyte and macrophage phenotype at the systemic level. [Fig. 3E-3F] Figure 3E shows that MEx regulates monocyte and macrophage phenotype at the systemic level, and Figure 3F shows that MEx regulates monocyte and macrophage phenotype at the systemic level.
[0025] [Figure 4A-4B] Figure 4A shows that adoptive transfer of MEx-pretreated bone marrow-derived monocytes protects mice from pulmonary fibrosis. Figure 4B shows that adoptive transfer of MEx-pretreated bone marrow-derived monocytes protects mice from pulmonary fibrosis. [Fig. 4C-4D] Figure 4C shows that adoptive transfer of MEx-pretreated bone marrow-derived monocytes protects mice from pulmonary fibrosis. Figure 4D shows that adoptive transfer of MEx-pretreated bone marrow-derived monocytes protects mice from pulmonary fibrosis. [Fig. 4E-4F]Figure 4E shows that adoptive transfer of MEx-pretreated bone marrow-derived monocytes protects mice from pulmonary fibrosis. Figure 4F shows that adoptive transfer of MEx-pretreated bone marrow-derived monocytes protects mice from pulmonary fibrosis.
[0026] [Figure 5A] FIG. 5A shows that MEx treatment reduces apoptosis. [Figure 5B-5D] Figure 5B shows that MEx treatment reduces apoptosis, Figure 5C shows that MEx treatment reduces apoptosis, and Figure 5D shows that MEx treatment reduces apoptosis. [Figure 6A] FIG. 6A shows the purification, isolation and characterization of exosomes. [Figure 6B-6C] Figure 6B shows the purification, isolation and characterization of exosomes. Figure 6C shows the purification, isolation and characterization of exosomes.
[0027] [Figure 7A-7B] Figure 7A shows that MEx treatment at the end of inflammation reverses fibrosis, and Figure 7B shows that MEx treatment at the end of inflammation reverses fibrosis. [Figure 7C-7D] Figure 7C shows that MEx treatment at the end of inflammation reverses fibrosis, and Figure 7D shows that MEx treatment at the end of inflammation reverses fibrosis. [Figure 8] Figure 8 shows a representative in vivo gating strategy for lung macrophages, monocytes and bone marrow-derived monocytes. [Figure 9] FIG. 9 shows that labeled MEx can be detected in bone marrow.
[0028] BRIEF DESCRIPTION OF THE DRAWINGS The accompanying drawings are not intended to be drawn to scale. In the drawings, each identical or nearly identical component illustrated in the various figures is represented by a like numeral. For clarity, not every component is labeled in every drawing. The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with the color drawing(s) will be provided by the U.S. Patent Office upon request and payment of the necessary fee. In the drawings:
[0029] Figure 1A to 1D show that MEx treatment at the onset of inflammation prevents fibrosis. (Figure 1A) 10-14 week old C57BL / 6 mice received intratracheal bleomycin (60 μg) or 0.9% saline (NS) on day 0, followed by a bolus dose of IV MEx (Bleo+MEx), NS (Bleo+NS), FEx (Bleo+FEx), or iodixanol (IDX 1:9 dilution, Bleo+IDX). Results were compared to control groups that received either NS (vehicle, control) or NS followed by a dose of MEx (control+MEx). Mice were sacrificed on day 14. (Figure 1B) Lung sections were stained with Masson's trichrome. Inserts were taken at 100X magnification. Bleo+NS, Bleo+FEx, and Bleo+IDX showed disruption of lung architecture, thickening of alveolar septa, and fibrotic changes. (Figure 1C) Administration of MEx to bleomycin-treated mice substantially reduced fibrosis and alveolar distortion. Findings were similar to control or control+Mex groups. Pulmonary fibrosis was measured by Ashcroft score on day 14. (Figure 1D) Collagen deposition was assessed by Sircol assay and expressed as mg / ml of left lung homogenate. n=3-4 per group, *p<0.05; ****p<0.0001 vs. bleomycin-treated group. Scale bar=100 μm.
[0030] Figures 2A to 2E show that MEx modulates alveolar macrophage phenotype and blunted inflammation. Whole lung RT-qPCR showed increased expression of macrophage Ccl-2 and arginase-1 (Arg1) markers on days 7 (Figure 2A) and 14 (Figure 2B), while their levels were similar to controls with MEx treatment. Interleukin-6 expression showed a similar trend, but its reduction with MEx treatment did not reach statistical significance. Levels of residual TGF-β did not change among the three groups. Results are expressed relative to control expression. Mean ± SEM, n = 4–8 per group. *p < 0.05; **p < 0.01 vs. bleomycin-exposed mice. (Fig. 2C and 2D) Immunoluminescence (IF) analysis of lung sections using antibodies against Arg1 (green) and CD206 (red), markers of M2-like activation, showed an increase in mean luminescence intensity (MFI) in bleomycin mice, while the intensity was similar to control levels with MEx treatment. Nuclear staining was performed with Dapi. Images were acquired at a magnification of x10. Mean luminescence intensity (Dapi staining) was normalized to cell number. Analysis performed was with Image J software. N=5 per group, *p<0.05; **p<0.01 vs. bleomycin-exposed mice. (Fig. 2E) Cumulative data and representative graphs show CD206 +ve Alveolar macrophages (AM) (CD45 +ve CD11b -ve CD11c +ve CD206 +ve The percentage of CD206 cells is depicted. +ve The number of AMs was reduced with MEx treatment but did not reach statistical significance compared to the bleomycin-exposed group. Representative histograms normalized to the mode. Mean ± SEM of n = 4–5 per group, **p < 0.01 vs. bleomycin-exposed mice. Abbreviations: Dapi, 40,6-diamidino-2-phenylindole.
[0031] Figures 3A to 3F show that MEx modulates monocyte and macrophage phenotype at the systemic level, demonstrating that MEx restores alveolar macrophages and inflammatory monocyte populations in the lung. (Figure 3A) Cytometric analysis in whole lungs 7 days after injury showed a reduction in AM numbers (CD45 +ve CD11b -ve CD11c +ve (Figure 3B) This indicates that Ly6C high infiltrating or classical monocytes (Ly6C high CCR-2 +ve ) at day 14. (Fig. 3C) AM numbers increased and (Fig. 3D) classical monocyte numbers were reduced to approximately half of the levels observed in the NS-treated (control) group of mice (mean difference: 1.7% ± 0.44, p < 0.01). MEx treatment not only led to a recovery of AM population numbers but also regulated the monocyte phenotype in the lungs to levels comparable to the control group analyzed at days 7 and 14. Mean ± SEM n = 4–5 per group, *p < 0.05; **p < 0.01; ***p < 0.001 vs. bleomycin-exposed mice. The gating strategy was performed according to the fluorescence minus one control (see Fig. 8). To investigate the systemic effects of MEx, myeloid characteristics of the bone marrow were analyzed by flow cytometry. CD45 in the three groups +ve Despite comparable numbers of cells (data not shown), (Figure 3E and Figure 3F) classical monocytes were increased in the bleomycin-exposed group of mice (mean difference: 17.6% ± 3.6, p < 0.001 vs. bleomycin-exposed mice), whereas regulatory monocytes exhibited a two-fold decrease in bleomycin-exposed mice compared to control mice (mean difference: 18% ± 5.7, p < 0.05 vs. bleomycin-exposed mice). On the other hand, MEx treatment led to a decrease in inflammatory monocytes and a shift from an inflammatory to a regulatory (Ly6C low CCR-2-ve) phenotype, similar to the levels observed in control mice (mean difference: 10.25% ± 4.2, p < 0.05 and 13.39% ± 5.76, p < 0.05 vs. bleomycin-exposed mice). n=4–7 per group, *p<0.05; **p<0.01; ***p<0.001 vs. bleomycin-exposed mice.
[0032] Figure 4A to Figure 4F show that adoptive transfer of MEx pre-treated bone marrow-derived monocytes protects mice from pulmonary fibrosis. The potential therapeutic effect of ex vivo treated BMDMo and AM in preventing fibrosis was explored. (Figure 4A) BMDMo were isolated from 6-8 week old FVB mice and cultured ex vivo for 3 days, with MEx (1 × 10 per 100 mm plate) on day 1, D1, and day 2, D2. 6 MSCs were treated with NS (equivalent to EVs generated by 100% MSCs) or medium alone and stained with Dil on day 3, D3. Cells were adoptively transferred intravenously into C57BL / 6 mice at a 1:1 ratio on days 0 and 3 after intratracheal instillation of bleomycin. Mice were sacrificed on day 14. Data are compared to bleomycin-exposed mice that had received NS only (bleomycin). (Figure 4B) Flow cytometry analysis of BMDMo after 3 days of culture showed >90% CD45 +ve CD11b +ve cells. (Fig. 4C) Dil-labeled BMDMo were detected in the lungs 14 days after injection. Images were obtained at a magnification of x20. (Fig. 4D to Fig. 4F) Fibrosis was improved in mice receiving MEx pre-treated monocytes (BMDMo+MEx) compared to NS (bleomycin). Mice injected with MEx-treated AM (AM+MEx) exhibited substantial fibrotic changes. Administration of untreated BMDMo (BMDM+medium) led to a mild improvement in fibrosis and collagen levels compared to the NS-treated group of mice. The reduction in collagen deposition did not reach statistical significance compared to NS-treated mice. Similar results were seen at collagen levels. Arrows indicate Dil-labeled monocytes. Between-group comparison: *p<0.05, **p<0.01, ***p<0.001, ****p<0.001. Scale bar=100 μm. Abbreviations: Dil, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (‘Dil’; DilC18(3)).
[0033] Figures 5A to 5D show that MEx treatment reduces apoptosis. (Figures 5A and 5B) Tunel staining in whole lung sections shows increased apoptosis (green) in bleomycin-exposed groups of mice compared to control (NS) and bleomycin+MEx. Nuclei were stained with Dapi. Images were acquired at a magnification of x20. MFI was quantified using Image J software and normalized for Dapi. *p<0.05, **p<0.01 vs. bleomycin-exposed mice. (Figure 5C) Annexin V / PI staining in whole lungs shows increased apoptosis (Annexin V+PI-) in bleomycin-exposed mice compared to control and bleomycin+MEx mice. (Figure 5D) In vitro apoptosis was measured using the Caspase-Glo® 3 / 7 assay. More apoptosis is seen in bleomycin-exposed human alveolar epithelial cells. This effect is abolished with MEx treatment. Relative luminescence units were used as a proxy for apoptosis, and the Y-axis represents luminescence compared to control, n=8 per group, **p<0.01; ****P<0.0001 vs bleomycin-exposed mice.
[0034] Figure 6A to 6C show the purification, isolation and characterization of exosomes. Conditioned medium (CM) from BMSCs or HDFs was differentially centrifuged and concentrated through tangential flow filtration. The concentrated (50x) CM was floated on an iodixanol (OptiPrep™, IDX) cushion gradient. The purified EV population in fraction 9 was used for analysis. (Figure 6A) Heterogeneous EV morphology seen by transmission electron microscopy (TEM) (x30,000g, scale bar = 100 nm). (Figure 6B) Nanoparticle tracking analysis (NTA) was used to assess EV concentration. Representative size distribution of BMSC-EVs and HDF-EVs in fraction 9 gradient. (Figure 6C) Western blot analysis of IDX cushion gradient fractions (7-10) using antibodies against exosome markers flotillin (FLOT-1), CD63 and Alix.
[0035] Figures 7A to 7D show that MEx treatment at the end of inflammation reverses fibrosis. (Figure 7A) MEx was administered 7 days after administration of bleomycin and mice were sacrificed on day 14. (Figures 7B and 7C) Lung sections from control, bleomycin and bleo+MEx mice were analyzed for histology and (Figure 7D) collagen deposition. MEx treatment resulted in a reduction in fibrosis and collagen deposition on day 7. Data represent mean ± SEM of n=4 per group, *p<0.05; ****p<0.0001 vs. bleomycin-exposed mice. Scale bar=100 μm.
[0036] Figure 8 shows a representative in vivo gating strategy for pulmonary macrophages, monocytes and bone marrow-derived monocytes. Cells were isolated from whole lungs after enzymatic digestion. Lung aggregates and cellular debris were excluded based on forward and side scatter parameters. Immune cells were identified by CD45 staining. Alveolar macrophages (AMs) express CD45 +ve CD11b -ve CD11c +ve A sequential gating strategy was used to identify the CD206 population. +ve To identify monocyte subpopulations, CD45 +ve The non-alveolar macrophage subset of cells (CD11b int CD11C 低 ) and a sequential gating strategy was implemented for CCR-2 +ve Ly6C 高 and CCR-2 -ve Ly6C 低 Populations were gated to reflect classical or non-classical monocyte phenotypes, respectively. The BMDMo gating strategy was similar to above, except for CD11c and CD206 (markers for AM) staining. The gating strategy was performed according to the fluorescence-minus-one control.
[0037] Figure 9 shows that labeled MEx can be detected in bone marrow. Membrane dye-labeled EVs were injected IV into mice and animals were sacrificed 2 hours after injection. MEx was detected in BM cytospins (labeled MEx). Injected free dye and dye-stained EV-free supernatant were used as controls. Counterstaining was performed with Dapi. Images were acquired at a magnification of x60.
[0038] DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS The present disclosure is based, at least in part, on the discovery that mesenchymal stromal cell (also referred to herein interchangeably as "mesenchymal stem cell" or "MSC") exosomes (also referred to herein as "Mex"), when administered (e.g., systemically) to a subject, can modulate monocyte phenotype in bone marrow, resulting in a larger subpopulation of regulatory monocytes instead of pro-inflammatory monocytes. Furthermore, monocytes (e.g., bone marrow-derived monocytes) treated in vitro with MSC exosomes have a therapeutic effect in fibrotic lungs when administered to a subject with pulmonary fibrosis.
[0039] Some aspects of the present disclosure provide monocytes treated with isolated mesenchymal stem cell (MSC) exosomes. "Monocytes" are a type of white blood cell (also called "white blood cell") that can differentiate into macrophages and myeloid dendritic cells. In vertebrates, monocytes are part of the innate immune system, but can also affect the process of adaptive immunity.
[0040] Monocytes comprise 2% to 10% of all white blood cells in the human body and play multiple roles in immune function, including, but not limited to, replenishing resident macrophages under normal conditions; migration in response to inflammatory signals from sites of infection in tissues; and differentiation into macrophages or dendritic cells to effect an immune response.
[0041] Monocytes are a heterogeneous population of cells and can be divided into subpopulations with different phenotypes and functions. In some embodiments, human monocytes are subdivided into phenotypically and functionally distinct subpopulations based on the expression of lipopolysaccharide (LPS) receptor (CD14) and CD16 (Fc gamma receptor III) (e.g., as described in Ziegler-Heitbrock et al., Blood, vol. 116, no. 16, pp. e74-e80, 2010 and Gordon et al., Nature Reviews Immunology, vol. 5, no. 12, pp. 953-964, 2005, which are incorporated herein by reference). In healthy individuals, approximately 80-90% of monocytes are highly CD14 positive and CD16 negative (CD14 ++ CD16 - ) CD14 ++ CD16 - Monocytes are referred to herein as "classical monocytes" or "regulatory monocytes." The remaining 10-20% of monocytes are CD16 positive and classified as "pro-inflammatory monocytes." Pro-inflammatory monocytes are further classified as CD14 ++ CD16 + and CD14 + CD16 ++ It can be subdivided into CD14 cells. ++ CD16 + Monocytes are also called "intermediate monocytes"; CD14 + CD16 ++Monocytes are also referred to as "non-classical monocytes".Compared with CD16-negative conventional monocytes, CD16-positive monocytes (proinflammatory monocytes) express higher levels of major histocompatibility complex (MHC) class II antigens, adhesion molecules, chemokine receptors, and proinflammatory cytokines such as TNF-α, but lower levels of anti-inflammatory cytokines (e.g., IL-10) (e.g., as described in Kawanaka et al., Arthritis & Rheumatism, vol. 46, no. 10, pp. 2578-2586, 2002 and Ziegler-Heitbrock et al., Immunology Today, vol. 17, no. 9, pp. 424-428, 1996, which are incorporated herein by reference).Proinflammatory monocytes are elevated in various pathological conditions, including in inflammatory and infectious diseases, cancer, and coronary heart disease. In mice, monocytes can also be divided into two subpopulations: proinflammatory monocytes (Cx3CR1 低 , CCR2 + , Ly6C 高 ); and human CD14 ++ CD16 - The regulatory monocyte (Cx3CR1 高 , CCR2 - , Ly6C 低 ).
[0042] Monocytes are generated by bone marrow from precursors called monoblasts, which are bipotential cells differentiated from hematopoietic stem cells. Monocytes circulate in the bloodstream for about 1 to 3 days, and then typically migrate to tissues throughout the body, where they differentiate into macrophages and dendritic cells. In some embodiments, the monocytes treated with MSC exosomes described herein are from bone marrow (e.g., isolated from bone marrow). In some embodiments, the monocytes treated with MSC exosomes described herein are from a specific tissue (e.g., isolated from a specific tissue such as lung).
[0043] "Exosomes" are membrane (e.g., lipid bilayer) vesicles released from cells (e.g., any eukaryotic cell). Exosomes are present in eukaryotic fluids, including blood, urine, and cell culture media. The exosomes of the present disclosure are released from mesenchymal stem cells (MSCs) and are interchangeably referred to as "mesenchymal stem cell exosomes" or "MSC exosomes."
[0044] "Mesenchymal stem cells (MSCs)" are progenitor cells that have the capacity to differentiate into neurons, adipocytes, chondrocytes, osteoblasts, muscle cells, cardiac tissue, and other endothelial or epithelial cells. (See, e.g., Wang et al., , Stem Cells 2004;22(7);1330-7; McElreavey;1991 Biochem Soc Trans (1);29s; Takechi, Placenta 1993 March / April; 14 (2); 235-45; Takechi, 1993; Kobayashi; Early Human Development;1998; July 10; 51 (3); 223-33; Yen; Stem Cells; 2005; 23 (1) 3-9.) These cells may be phenotypically defined by gene or protein expression. These cells have been characterized as expressing (and thus being positive for) one or more of CD13, CD29, CD44, CD49a, b, c, e, f, CD51, CD54, CD58, CD71, CD73, CD90, CD102, CD105, CD106, CDw119, CD120a, CD120b, CD123, CD124, CD126, CD127, CD140a, CD166, P75, TGF-bIR, TGF-bIIR, HLA-A, B, C, SSEA-3, SSEA-4, D7 and PD-L1. These cells have also been characterized as not expressing (and thus being negative for) CD3, CD5, CD6, CD9, CD10, CD11a, CD14, CD15, CD18, CD21, CD25, CD31, CD34, CD36, CD38, CD45, CD49d, CD50, CD62E, L, S, CD80, CD86, CD95, CD117, CD133, SSEA-1, and ABO. Thus, MSCs may be characterized phenotypically and / or functionally according to their differentiation potential.
[0045] MSCs may be harvested from a number of sources, including but not limited to bone marrow, adipose tissue, blood, periosteum, dermis, umbilical cord blood and / or matrix (e.g., Wharton's jelly), and placenta. For example, MSCs may be isolated from commercially available bone marrow aspirates. Enrichment of MSCs in a population of cells may be achieved using methods known in the art, including but not limited to luminescence-activated cell sorting (FACS). Methods for harvesting MSCs are described in the art, for example, U.S. Patent No. 5,486,359, which is incorporated herein by reference.
[0046] Commercially available media may be used for the growth, culture, and maintenance of MSCs. Such media include, but are not limited to, Dulbecco's Modified Eagle's Medium (DMEM). Components of such media that are useful for the growth, culture, and maintenance of MSCs, fibroblasts, and macrophages include, but are not limited to, amino acids, vitamins, carbon sources (natural and unnatural), salts, sugars, hydrolysates of plant origin, sodium pyruvate, detergents, ammonia, lipids, hormones or growth factors, buffers, unnatural amino acids, sugar precursors, indicators, nucleosides and / or nucleotides, butyric acid or organics, DMSO, animal-derived products, gene inducers, unnatural sugars, regulators of intracellular pH, betaine or osmoprotectants, trace elements, minerals, unnatural vitamins. Additional components that can be used to supplement commercially available tissue culture media include, for example, animal serum (e.g., fetal bovine serum (FBS), fetal calf serum (FCS), horse serum (HS)), antibiotics (e.g., penicillin, streptomycin, neomycin sulfate, amphotericin B, blasticidin, chloramphenicol, amoxicillin, bacitracin, bleomycin, cephalosporin, chlortetracycline, zeocin, and puromycin), and glutamine (e.g., L-glutamine). Mesenchymal stem cell survival and growth also depend on maintaining an appropriate aerobic environment, pH, and temperature. MSCs can be maintained using methods known in the art, for example, as described in Pittenger et al., Science, 284:143-147 (1999), which is incorporated herein by reference.
[0047] In some embodiments, the MSC exosomes used to treat monocytes are isolated. As used herein, an "isolated exosome" is an exosome that is physically separated from its natural environment. The isolated exosome may be physically separated, in whole or in part, from the tissue or cell (e.g., MSC) with which it naturally occurs. In some embodiments, the isolated MSC exosomes are isolated from the culture medium of MSCs from human bone marrow, umbilical cord Wharton's jelly, or adipose tissue. Such culture medium is referred to herein as "MSC-conditioned medium". In some embodiments, the isolated exosomes may be cell-free, such as MSCs, or conditioned medium-free or substantially free, or free of any biological contaminants, such as proteins. Typically, the isolated exosomes are provided at a higher concentration than exosomes present in unmanipulated conditioned medium.
[0048] In some embodiments, the isolated MSC exosomes described herein comprise one or more (e.g., 1, 2, 3, 4, or 5 or more) known exosome markers. In some embodiments, the known exosome markers are selected from the group consisting of: FLOT1 (flotillin 1, Uniprot ID: O75955), CD9 (CD9 antigen, Uniprot ID: P21926), and CD63 (CD63 antigen, Uniprot ID: P08962).
[0049] In some embodiments, the isolated MSC exosome is substantially free of contaminants (e.g., protein contaminants). If the isolated MSC exosome preparation contains less than 20%, 15%, 10%, 5%, 2%, 1%, or less than 1% of any other substance (e.g., protein), the isolated MSC exosome is "substantially free of contaminants". In some embodiments, the isolated MSC exosome preparation is "substantially free of contaminants" with respect to contaminants (e.g., protein) if the isolated MSC exosome preparation is at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, at least 99.9% pure.
[0050] "Protein contaminants" refer to proteins that are not associated with isolated exosomes and that do not contribute to the biological activity of the exosomes. Protein contaminants are also referred to herein as "non-exosomal protein contaminants."
[0051] In some embodiments, the isolated MSC exosomes used in accordance with the present disclosure have a diameter of about 30-150 nm. For example, the isolated MSC exosomes may have a diameter of 30-150 nm, 30-140 nm, 30-130 nm, 30-120 nm, 30-110 nm, 30-100 nm, 30-90 nm, 30-80 nm, 30-70 nm, 30-60 nm, 30-50 nm, 30-40 nm, 40-150 nm, 40-140 nm, 40-130 nm, 40-120 nm, 40-110 nm, 40-100 nm, 40-90 nm, m, 40~80nm, 40~70nm, 40~60nm, 40~50nm, 50~150nm, 50~140nm, 50~130nm, 50~120nm, 50~110nm, 50~100nm, 50~ 90nm, 50~80nm, 50~70nm, 50~60nm, 60~150nm, 60~140nm, 60~130nm, 60~120nm, 60~110nm, 60~100nm, 60~90nm, 60~80nm, 60~70nm, 70~150nm, 70~140nm, 70~130nm, 70~120nm, 70~110nm, 70~100nm, 70~90nm, 70~80nm, 80~15 0nm, 80~140nm, 80~130nm, 80~120nm, 80~110nm, 80~100nm, 80~90nm, 90~150nm, 90~140nm, 90~130nm, 90~120nm m, 90-110 nm, 90-100 nm, 100-150 nm, 100-140 nm, 100-130 nm, 100-120 nm, 100-110 nm, 110-150 nm, 110-140 nm, 110-130 nm, 110-120 nm, 120-150 nm, 120-140 nm, 120-130 nm, 130-150 nm, 130-140 nm, or 140-150 nm. In some embodiments, the isolated MSC exosomes may have a diameter of about 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 110 nm, 120 nm, 130 nm, 140 nm, or 150 nm. In some embodiments, the isolated MSC exosomes exhibit a biconcave morphology.
[0052] As described herein, isolated MSC exosomes can be used to treat monocytes to modulate monocyte phenotype (e.g., both in vitro and in vivo, such as in bone marrow). "Treating monocytes with isolated MSC exosomes" means contacting monocytes with MSC exosomes (e.g., for a period of time). In some embodiments, the treatment (i.e., contacting) is performed in vitro. For example, monocytes may be cultured in vitro, and isolated MSC exosomes may be added to the culture such that the monocytes contact the isolated MSC exosomes. In some embodiments, the treatment (i.e., contacting) is performed ex vivo. For example, monocytes may be isolated from the bone marrow of a subject, and isolated MSC exosomes may be added to the monocytes such that the monocytes contact the isolated MSC exosomes. In some embodiments, the treatment (i.e., contacting) is performed in vivo. For example, isolated MSC exosomes may be administered to a subject (eg, via intravenous injection) where they reach the marrow and come into contact with monocytes in the bone marrow.
[0053] In some embodiments, monocytes are treated (i.e., contacted) with MSC exosomes for at least 1 hour (e.g., at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, at least 100 hours, or longer). In some embodiments, monocytes are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 , 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 hours or more.
[0054] In some embodiments, monocytes are polarized to a pro-inflammatory state as a result of environmentally or developmentally induced injury, and the polarity is adjusted to a regulatory phenotype upon contact with isolated MSC exosomes. In some embodiments, the monocytes are pro-inflammatory monocytes before being treated (i.e., contacted) with isolated MSC exosomes, and are regulatory monocytes after being treated (i.e., contacted) with isolated MSC exosomes. In some embodiments, a mixture of pro-inflammatory and regulatory monocytes is contacted with isolated MSC exosomes, and the treatment results in a higher ratio of regulatory monocytes (e.g., at least 10% higher) in the mixture that is treated with isolated MSC exosomes. For example, the ratio of regulatory monocytes may be at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 2-fold, at least 5-fold, at least 10-fold, at least 100-fold, or higher after treatment with MSC exosomes compared to before treatment with isolated MSC exosomes. In some embodiments, the ratio of regulatory monocytes is 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 5-fold, 10-fold, 100-fold, or higher after treatment with MSC exosomes compared to before treatment with isolated MSC exosomes.
[0055] Further provided herein is the use of isolated MSC exosome-treated monocytes for treating disease (e.g., fibrotic disease such as pulmonary fibrosis or autoimmune disease). In some embodiments, isolated MSC exosome-treated monocytes are used in the manufacture of a medicament for treating disease (e.g., fibrotic disease or autoimmune disease). Also provided is a composition comprising isolated MSC exosome-treated monocytes. In some embodiments, isolated MSC exosome-treated monocytes are formulated in a composition for treating disease (e.g., fibrotic disease or autoimmune disease).
[0056] In some embodiments, the composition comprising monocytes treated with isolated MSC exosomes further comprises a second agent.In some embodiments, the second agent is an effective therapeutic agent for the disease treated by monocytes.For example, the second agent may be any agent that can be used in the prevention, treatment and / or management of fibrotic disease or autoimmune disease, such as those described herein.In some embodiments, the second agent is isolated MSC exosomes.
[0057] In some embodiments, the second agent is an agent known to have therapeutic effect on fibrotic disease.The exemplary second agent that may be used to treat fibrotic disease includes, but is not limited to: nintedanib (tyrosine kinase inhibitor), pirfenidone, antifibrotic agent, and / or anti-inflammatory agent.In some embodiments, for pulmonary fibrosis, other types of treatment, such as oxygen supplementation, may be used in conjunction with the therapeutic agent described herein.
[0058] In some embodiments, the second agent is an agent known to have a therapeutic effect on autoimmune disease. Such agents include, but are not limited to, nonsteroidal anti-inflammatory drugs, glucocorticoids, metrotrexate, leflunomide, anti-TNF biologics (e.g., antibodies such as infliximab, adalimumab, golimumab, or certolizumab pegol). Drugs for treating autoimmune disease are known in the art, and are, for example, as described in Li et al., Front Pharmacol. 2017; 8: 460, which is incorporated herein by reference.
[0059] In some embodiments, the isolated MSC exosome-treated monocytes and the second agent are formulated in the same composition. In some embodiments, the isolated MSC exosome-treated monocytes and the second agent are formulated in separate compositions. In some embodiments, the isolated MSC exosome-treated monocytes and the second agent are administered to a subject simultaneously. In some embodiments, the isolated MSC exosome-treated monocytes and the second agent are administered separately. In some embodiments, the isolated MSC exosome-treated monocytes are administered before the second agent. In some embodiments, the isolated MSC exosome-treated monocytes are administered after the second agent.
[0060] In some embodiments, the composition comprising the isolated MSC exosome-treated monocytes is a pharmaceutical composition. In some embodiments, the composition further comprises a pharma- ceutically acceptable concentration of salt, buffer, preservative, or compatible carrier.
[0061] A pharmaceutically acceptable carrier is a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, which is involved in carrying or transporting a prophylactically or therapeutically active agent. Each carrier must be "acceptable" in the sense that it is compatible with the other ingredients of the formulation and is not harmful to the subject. Some examples of materials that can serve as pharmaceutically acceptable carriers include sugars such as lactose, glucose and sucrose; glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; buffers such as magnesium hydroxide and aluminum hydroxide; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer; and other non-toxic compatible substances used in pharmaceutical formulations.
[0062] The composition may take the form of an aqueous suspension, solution or emulsion in an oily or aqueous vehicle, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate or triglycerides. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase solubility. Alternatively, the exosomes may be in lyophilized or other powder or solid form, to be constituted with a suitable vehicle, for example, sterile pyrogen-free water, before use.
[0063] Another aspect of the present disclosure provides a method of treating a disease (e.g., a fibrotic disease or an autoimmune disease), comprising administering an effective amount of monocytes to a subject in need thereof, wherein the monocytes are treated (e.g., for at least 2 hours) with isolated mesenchymal stem cell (MSC) exosomes prior to administration using the methods described herein. In some embodiments, the method further comprises isolating monocytes from the subject (e.g., from the bone marrow of the subject), such that the monocytes can be treated with isolated MSC exosomes prior to administration to the subject.
[0064] "Treating" or "treatment" of a disease (e.g., a fibrotic or autoimmune disease) includes, but is not limited to, preventing, reducing, or arresting the onset of a fibrotic or autoimmune disease, reducing or eliminating the symptoms of a fibrotic or autoimmune disease, or preventing a fibrotic or autoimmune disease.
[0065] An "effective amount" is the amount of agent that achieves a desired outcome. The absolute amount will depend on a variety of factors, including the material selected for administration, whether administration is in single or multiple doses, individual patient parameters, including age, physical condition, size, weight, and stage of disease. These factors are well known to those of skill in the art and can be addressed with no more than routine experimentation.
[0066] In some embodiments, the effective amount is the dosage of the agent that does not cause toxicity to the subject.In some embodiments, the effective amount is the dosage of the agent that causes reduced toxicity to the subject.Methods for measuring toxicity are well known in the art (e.g., liver, spleen and / or kidney biopsy / histology; alanine transferase, alkaline phosphatase and bilirubin assay for liver toxicity; and creatinine level for kidney toxicity).
[0067] A subject is intended to mean a human or a vertebrate or a mammal, including, but not limited to, rodents, such as rats or mice, dogs, cats, horses, cows, pigs, sheep, goats, turkeys, chickens, and primates, such as monkeys. In some embodiments, the subject is a human. In some embodiments, the subject is a companion animal. "Companion animal" as used herein refers to pets and other domestic animals. Non-limiting examples of companion animals include dogs and cats; livestock such as horses, cattle, pigs, sheep, goats, and chickens; and other animals such as mice, rats, guinea pigs, and hamsters. The methods of the present disclosure are useful for treating a subject in need thereof. The subject may have a disease described herein that is suitable for treatment with the monocytes described in this disclosure, or they may be at risk of developing such a disease.
[0068] In some embodiments, the subject is a human subject. In some embodiments, the subject is a human infant. For example, the subject may be a newborn, and in particular a newborn born at a low gestational age. As used herein, a human newborn refers to a human from birth to about 4 weeks of age. As used herein, a human infant refers to a human from about 4 weeks to about 3 years of age. As used herein, a low gestational age refers to a birth (or delivery) that occurs before the normal gestational age for a given species. In humans, the total gestational age is about 40 weeks, and may range from 37 weeks to more than 40 weeks. A low gestational age in humans is similar to preterm birth and is defined as a birth that occurs before 37 weeks of gestation. Thus, the present disclosure contemplates the prevention and / or treatment of subjects born before 37 weeks of gestation, including those born at shorter gestational ages (e.g., before 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, or 25 weeks of gestation).
[0069] For infants or newborns, the present disclosure contemplates their treatment beyond the neonatal stage into childhood and / or adulthood. For example, in some embodiments, the subject treated with the method of the present disclosure is 3-18 years old. In some embodiments, the subject treated with the method of the present disclosure is 3-18, 3-17, 3-16, 3-15, 3-14, 3-13, 3-12, 3-11, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-18, 4-17, 4-16, 4-15, 4-14, 4-13, 4-12, 4-11, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5 , 5-18, 5-17, 5-16, 5-15, 5-14, 5-13, 5-12, 5-11, 5-10, 5-9, 5-8, 5-7, 5-6, 6-18, 6-17, 6-16, 6-15, 6-14, 6-13, 6-12, 6-11, 6-10, 6-9, 6-8, 6-7, 7-18, 7-17, 7-16, 7-15, 7-14, 7-13, 7-12, 7-11, 7-10, 7-9, 7-8, 8-18, 8-17, 8-16, 8-15, 8-14, 8-13, 8-12, 8-11, 8-10, 8-9, 9-18, 9-17, 9-16, 9-15, 9-14, 9-13, 9-12, 9-11, 9-10, 10-18, 10-17, 10-16, 10-15, 10-14, 10-13, 10-12, 10-11, 11-18, 11-17, 11 The subject may be between 16, 11 and 15, 11 and 14, 11 and 13, 11 and 12, 12 and 18, 12 and 17, 12 and 16, 12 and 15, 12 and 14, 12 and 13, 13 and 18, 13 and 17, 13 and 16, 13 and 15, 13 and 14, 14 and 18, 14 and 17, 14 and 16, 14 and 15, 15 and 18, 15 and 17, 15 and 16, 16 and 18, 16 and 17, or 17 and 18 years old. In some embodiments, the subject is an adult, e.g., 18 years old or older.
[0070] Certain subjects may have a genetic predisposition to a particular form of a disease (or condition) described herein (e.g., an autoimmune disease or a fibrotic disease), and those subjects may also be treated in accordance with the present disclosure.
[0071] With respect to newborns, and particularly newborns of low gestational age, the present disclosure contemplates administration of the isolated MSC exosome-treated monocytes or compositions comprising same within 1 year, 11 months, 10 months, 9 months, 8 months, 7 months, 6 months, 5 months, 4 months, 3 months, 2 months, 1 month, 4 weeks, 3 weeks, 2 weeks, 1 week, 6 days, 5 days, 4 days, 3 days, 2 days, 1 day, 12 hours, 6 hours, 3 hours, or 1 hour of birth. In some embodiments, the isolated MSC exosome-treated monocytes or compositions comprising same are administered within 1 hour of birth (e.g., within 1 hour, within 55 minutes, within 50 minutes, within 45 minutes, within 40 minutes, within 35 minutes, within 30 minutes, within 25 minutes, within 20 minutes, within 15 minutes, within 10 minutes, within 5 minutes, or within 1 minute). In some embodiments, the isolated MSC exosome-treated monocytes or a composition comprising such monocytes are administered to a subject shortly after birth.
[0072] The present disclosure further contemplates administration of the isolated MSC exosome-treated monocytes or compositions comprising the same, even in the absence of symptoms indicative of a disease or disorder described herein.
[0073] In some embodiments, the isolated MSC exosome-treated monocytes or compositions comprising such monocytes are administered once to a subject (e.g., a human subject). In some embodiments, repeated administration of the isolated MSC exosome-treated monocytes or compositions comprising such monocytes is contemplated, including administration of the isolated MSC exosome-treated monocytes or compositions comprising such monocytes two, three, four, five or more times. In some examples, the isolated MSC exosome-treated monocytes or compositions comprising same may be administered continuously. Repeated or continuous administration may occur over a period of hours (e.g., 1-2, 1-3, 1-6, 1-12, 1-18, or 1-24 hours), days (e.g., 1-2, 1-3, 1-4, 1-5, 1-6, or 1-7 days), or weeks (e.g., 1-2, 1-3, or 1-4 weeks), depending on the severity of the condition being treated. When administration is repeated but not consecutive, the time between administrations may be a few hours (e.g., 4, 6, or 12 hours), days (e.g., 1, 2, 3, 4, 5, or 6 days), or weeks (e.g., 1, 2, 3, or 4 weeks). The time between administrations may be the same or different.
[0074] In some embodiments, the isolated MSC exosome-treated monocytes or compositions comprising such monocytes are administered at least once within 24 hours of birth and then at least once more within one week of birth. In some embodiments, the isolated MSC exosome-treated monocytes or compositions comprising such monocytes are administered at least once within one hour of birth and then at least once more within 3-4 days of birth.
[0075] The isolated MSC exosome-treated monocytes or compositions comprising such monocytes may be administered by any route that results in delivery to fibrotic organs and / or bone marrow. Systemic routes of administration, such as intravenous injection or continuous infusion, are preferred. Other suitable routes of administration include oral administration, intranasal administration, intratracheal administration, inhalation, intravenous administration, etc. Those skilled in the art will be aware of the usual routes for administration.
[0076] The isolated MSC exosome-treated monocytes or compositions comprising such monocytes may be formulated for parenteral administration by injection, including, for example, bolus injection or continuous infusion. Formulations for injection may be provided in unit dosage form, for example, in ampoules or multi-dose containers, with or without added preservatives. The compositions may take the form of aqueous suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase solubility. Alternatively, the exosomes may be in lyophilized or other powder or solid form for constitution with a suitable vehicle, for example, sterile pyrogen-free water, before use.
[0077] In some embodiments, when the second agent is not formulated in the same composition as the isolated MSC exosome-treated monocytes, the methods described herein further include administering an effective amount of a second agent (e.g., an agent for treating a fibrotic disease or an autoimmune disease). The second agent may also be administered by any suitable route, including systemic administration (e.g., intravenous infusion or injection), oral administration, intranasal administration, intratracheal administration, inhalation, and the like. Those skilled in the art will know the usual routes of administration for such second agents.
[0078] "Fibrotic disease" or "fibrosis" refers to a condition manifested by the formation of excess fibrous connective tissue in organs or tissues during repair or reaction processes.Non-limiting examples of fibrotic diseases include: systemic sclerosis (scleroderma), pulmonary fibrosis (e.g., cystic fibrosis or idiopathic pulmonary fibrosis), liver fibrosis (liver cirrhosis or biliary atresia), cardiac fibrosis (e.g., atrial fibrosis, endomyocardial fibrosis, or previous myocardial infarction), brain fibrosis (e.g., glial scar), kidney fibrosis, and bone marrow fibrosis. Other types of fibrotic diseases include, but are not limited to: arterial stiffness, arthrofibrosis (knee, shoulder, other joints), Crohn's disease (intestine), Dupuytren's contracture (hand, fingers), keloids (skin), mediastinal fibrosis (soft tissue of the mediastinum), myelofibrosis (bone marrow), Peyronie's disease (penis), nephrogenic systemic fibrosis (skin), progressive massive fibrosis (lung); complications of coal workers' pneumoconiosis, retroperitoneal fibrosis (soft tissue of the retroperitoneum), scleroderma / systemic sclerosis (skin, lung), and some forms of adhesive capsulitis (shoulder).
[0079] In some embodiments, the fibrotic disease is pulmonary fibrosis. "Pulmonary fibrosis" refers to a condition in which lung tissue is damaged and injured, resulting in thickening and hardening of lung tissue and reduced lung function. Pulmonary fibrosis can have a variety of causes. Pulmonary fibrosis is typically seen in subjects with bronchopulmonary dysplasia (BPD). In some embodiments, the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is characterized by scarring or thickening of the lungs without a known cause. It occurs most often in people aged 50-70 years. Its symptoms include shortness of breath, regular coughing (typically dry), chest pain, and reduced activity levels. For fibrotic diseases (e.g., pulmonary fibrosis), it is shown herein that administration of monocytes treated with isolated MSC exosomes at the initial or later stages of inflammation associated with fibrosis is both therapeutically effective against the disease.
[0080] In some embodiments, the isolated MSC exosome-treated monocytes reduce inflammation associated with fibrotic disease. Those skilled in the art are familiar with methods for assessing the degree of inflammation in fibrotic organs (e.g., lungs). In some embodiments, inflammation may be assessed by measuring the level of inflammation biomarkers in fibrotic organs or in blood. In some embodiments, inflammation in fibrotic organs (e.g., lungs) is reduced by at least 20% in subjects administered with isolated MSC exosome-treated monocytes compared to subjects not administered with isolated MSC exosome-treated monocytes. For example, inflammation may be reduced by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% in subjects administered with isolated MSC exosome-treated monocytes compared to subjects not administered with isolated MSC exosome-treated monocytes. In some embodiments, inflammation is reduced by 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100% in subjects administered isolated MSC exosome-treated monocytes compared to subjects not administered isolated MSC exosome-treated monocytes.
[0081] In some embodiments, the isolated MSC exosome-treated monocytes reduce apoptosis of epithelial cells in fibrotic organs (e.g., alveolar epithelial cells in the lungs). "Apoptosis" refers to the death of cells that occurs as a normal and controlled part of the growth or development of an organism. In some embodiments, the apoptosis of epithelial cells in fibrotic organs (e.g., alveolar epithelial cells in the lungs) is considered to be "reduced" if the number of alveolar epithelial cells undergoing apoptosis is reduced by at least 20% in subjects administered with isolated MSC exosome-treated monocytes compared to subjects not administered with isolated MSC exosome-treated monocytes. For example, apoptosis of epithelial cells in a fibrotic organ (e.g., alveolar epithelial cells in the lungs) may be considered to be "reduced" if the number of alveolar epithelial cells undergoing apoptosis is reduced by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% in a subject administered isolated MSC exosome-treated monocytes compared to a subject not administered isolated MSC exosome-treated monocytes. In some embodiments, apoptosis of epithelial cells in a fibrotic organ (e.g., alveolar epithelial cells in the lungs) is considered to be "reduced" if the number of alveolar epithelial cells undergoing apoptosis is reduced by 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100% in a subject administered isolated MSC exosome-treated monocytes compared to a subject not administered MSC exosome-treated monocytes.
[0082] In some embodiments, the isolated MSC exosome-treated monocytes reduce pulmonary fibrosis.If the degree of pulmonary fibrosis (for example, indicated by collagen deposition on lung tissue) is reduced by at least 20% in the subject receiving the monocytes treated with MSC exosomes compared to the subject not receiving the monocytes treated with MSC exosomes, the pulmonary fibrosis is considered to be "reduced".For example, if the degree of pulmonary fibrosis (for example, indicated by collagen deposition on lung tissue) is reduced by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% in the subject receiving the monocytes treated with MSC exosomes compared to the subject not receiving the monocytes treated with MSC exosomes, the pulmonary fibrosis may be considered to be reduced. In some embodiments, pulmonary fibrosis is considered to be reduced if the extent of pulmonary fibrosis (e.g., as indicated by collagen deposition on lung tissue) is reduced by 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100% in a subject administered MSC exosome-treated monocytes compared to a subject not administered MSC exosome-treated monocytes.
[0083] An "autoimmune disease" is a condition in which the body's own immune system mistakenly attacks the body. Normally, the immune system can distinguish between foreign cells and the body's own cells. In an autoimmune disease, the immune system mistakenly identifies a part of the body (such as a joint or skin) as foreign. It releases proteins called autoantibodies that attack healthy cells. Some autoimmune diseases target only one organ. Type 1 diabetes damages the pancreas. Others, such as lupus, affect the entire body. Non-limiting examples of autoimmune diseases include: achalasia, Addison's disease, adult Still's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM / anti-TBM nephritis, antiphospholipid syndrome, autoimmune angioedema, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune thyroiditis ... Autoimmune urticaria, Axonal and neuronal neuropathy (AMAN), Baro's disease, Behçet's disease, Benign mucosal pemphigoid, Bullous pemphigoid, Castleman's disease (CD), Celiac disease, Chagas disease, Chronic inflammatory demyelinating polyneuropathy (CIDP), Chronic relapsing multifocal osteomyelitis (CRMO), Churg-Strauss syndrome (CSS) or eosinophilic granulomatosis (EGPA), Cicatricial pemphigoid, Cogan's syndrome, Cold agglutinin disease, Congenital cardiobronchial bronchitis (CD) CK, Coxsackie myocarditis, CREST syndrome, Crohn's disease, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressler syndrome, endometriosis, eosinophilic esophagitis (EoE), eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis, Graves' disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schönlein purpura (HSP), herpes gestationis or pemphigoid of gestationis (PG), hidradenitis suppurativa (HS) (acne contralateralis), hypogammaglobulinemia, IgA nephropathy, IgG4-related sclerosing disease, immune thrombocytopenic purpura (ITP), inclusion body myositis (IBM), interstitial cystitis (IC), juvenile arthritis, juvenile diabetes mellitus (type 1 diabetes), juvenile myositis (JM), Kawasaki disease,Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, lignified conjunctivitis, linear immunoglobulin A disease (LAD), lupus, chronic Lyme disease, Meniere's disease, microscopic polyangiitis (MPA), mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, multifocal motor neuropathy (MMN) or MMNCB, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neonatal lupus, neuromyelitis optica, neutropenia, ophthalmic cicatricial pemphigoid, optic neuritis, relapsing rheumatoid arthritis (PR), PANDAS, paraneoplastic cerebellar degeneration (PCD), paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, pars planitis (peripheral uveitis), Parsonage-Turner syndrome, pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia (PA), POEMS syndrome, polyarteritis nodosa, polyglandular syndrome type I, II, III, polymyalgia rheumatica, polymyositis, post-myocardial infarction syndrome, post-pericardiotomy syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, progesterone dermatitis, psoriasis, psoriatic arthritis, pure red cell aplasia (PRCA), pyoderma gangrenosum, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome (RLS), retroperitoneal Fibrosis, Rheumatic fever, Rheumatoid arthritis, Sarcoidosis, Schmidt syndrome, Scleritis, Scleroderma, Sjögren syndrome, Sperm and testicular autoimmunity, Stiff-body syndrome (SPS), Subacute bacterial endocarditis (SBE), Susac syndrome, Sympathetic ophthalmia (SO), Takayasu arteritis, Temporal arteritis / Giant cell arteritis, Thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome (THS), Transverse myelitis, Type 1 diabetes, Ulcerative colitis (UC), Undifferentiated connective tissue disease (UCTD), Uveitis, Vasculitis, Vitiligo, Vogt-Koyanagi-Harada disease, Wegener's granulomatosis (or granulomatosis with polyangiitis (GPA)).
[0084] In some embodiments, the autoimmune disease is selected from the group consisting of: rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), myasthenia gravis (MG), Graves' disease, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, autoimmune myocarditis, membranous glomerulonephritis, type I or II diabetes mellitus, juvenile onset diabetes, multiple sclerosis, Raynaud's syndrome, autoimmune thyroiditis, gastritis, celiac disease, vitiligo, hepatitis, primary biliary cirrhosis, inflammatory bowel disease. , spondyloarthropathy, experimental autoimmune encephalomyelitis, immune neutropenia, and cytokines typically seen in tuberculosis, sarcoidosis, and polymyositis, immune responses associated with delayed hypersensitivity mediated by T lymphocytes, polyarteritis, cutaneous vasculitis, pemphigus (e.g., pemphigus vulgaris, pemphigus foliaceus, or paraneoplastic pemphigus), pemphigoid, Goodpasture's syndrome, Kawasaki disease, systemic sclerosis, antiphospholipid syndrome, and Sjogren's syndrome.
[0085] Some of the aspects, advantages, features, and uses of the technology disclosed herein will be more fully understood from the following examples, which are intended to illustrate some advantages of the disclosure and to describe particular embodiments, but are not intended to exemplify the entire scope of the disclosure and, consequently, do not limit the scope of the disclosure.
[0086] example Idiopathic pulmonary fibrosis (IPF) is a chronic progressive respiratory disease whose underlying mechanisms are incompletely understood and which currently lacks effective treatments. Despite promising results with mesenchymal stromal cell (MSC) treatment in preventing pulmonary fibrosis, limitations of cell therapy continue to make cell-free therapies highly desirable. In preclinical models other than IPF, MSC extracellular vesicles (EVs) or, more specifically, exosomes (MEx) isolated from MSC secretomes have been shown to act as therapeutic vectors. The effects of MEx in IPF and their mechanism of action (MOA) are unknown.
[0087] Objective: The efficacy and MOA of MEx in a bleomycin IPF model were investigated. Methods: Exosomes isolated from human bone marrow MSCs (MEx) were infused into adult C57BL / 6 mice 0 or 7 days after intratracheal bleomycin instillation. Lung and bone marrow derived monocytes (BMDMo) were harvested on days 7 and 14 for histological, gene expression or cytometric analysis.
[0088] Measurements and Key Results MEx treatment either simultaneously with or 7 days after bleomycin exposure substantially prevented pulmonary fibrosis and collagen deposition. MEx treatment blunted inflammation and reduced classical (Ly6C high CCR-2) pulmonary fibrosis. +ve ) monocytes. Examination of the upstream effects of MEx revealed that MEx induced a transition from a classical to a regulatory monocyte phenotype in the bone marrow. Interestingly, adoptive transfer of MEx-pretreated BMDMo was sufficient to reduce fibrosis. In addition, MEx prevented alveolar epithelial cell apoptosis.
[0089] Conclusions: We showed that systemic treatment with MEx prevented fibrosis when administered during the early or late stages of inflammation. MEx was further shown to exert a systemic immunomodulatory effect by modulating monocyte phenotype in the bone marrow, which protected the lung from fibrosis. These results suggest the potential use of MEx for the cell-free treatment of fibrotic lung diseases.
[0090] introduction Idiopathic pulmonary fibrosis (IPF) is a chronic progressive respiratory disease with a prevalence of 0.5 to 27.9 per 100,000 person-years (1, 2). Lack of a complete understanding of the mechanisms underlying the disease may have contributed to the paucity of successful treatments. Despite two newly approved drugs, IPF remains fatal with a 5-year survival rate of less than 10% (3–6). In addition to pharmacological treatments, cell-based therapies such as mesenchymal stromal cells (MSCs) have also been explored (7–9). Despite the promising results of MSC therapy in preventing pulmonary fibrosis, limitations such as adverse immune responses, survival challenges, unexpected engraftment, and the potential for differentiation of MSCs into fibroblasts nevertheless continue to make cell-free therapies highly desirable (8–10).
[0091] It was previously demonstrated that the therapeutic potential of MSCs resides in their secretome, which is composed of a heterogeneous pool of bioactive molecules, often enclosed in extracellular vesicles (EVs). In preclinical models other than IPF, e.g. bronchopulmonary dysplasia, pulmonary hypertension and acute lung injury, EVs, or more specifically exosomes (MEx), isolated from MSC secretomes, have been shown to act as therapeutic vectors (7, 11-19).
[0092] The effect of MEx in IPF is unknown. A growing body of literature supports the role of circulating inflammatory monocytes and alveolar M2-like macrophages in the development and progression of pulmonary fibrosis (20, 21). In addition, recent reports of bleomycin-induced fibrosis models suggest a detrimental role for monocyte-derived alveolar macrophages (AMs) present in the lung after lung injury (21, 22). Whether MEx has any systemic and immunomodulatory effects on monocytes remains unknown. In addition, the source of action of MEx has yet to be defined.
[0093] This study showed that systemic therapy with purified MEx prevented pulmonary fibrosis when administered at early or late stages of inflammation (days 0 and 7 after bleomycin administration). Furthermore, systemic and organ-level effects of MEx in modulating macrophage and monocyte phenotype were revealed. MEx was demonstrated to exert antiapoptotic and immunomodulatory effects by shifting monocyte subpopulations in the bone marrow from a proinflammatory to a regulatory phenotype. The latter finding led to the discovery that even systemic delivery (adoptive transfer) of MEx-treated bone marrow-derived monocytes (BMDMo) prevented pulmonary fibrosis. This study provides mechanistic insight into the action of MEx and supports a systemic immunomodulatory potential that leads to a secondary antifibrotic effect in the lung.
[0094] method: Animal models, histology and cytometry All mice were housed and cared for in a pathogen-free facility. All animal experiments were approved by the Boston Children's Hospital Animal Core and Use Committee. C57BL / 6 mice (Charles Laboratories), 10–14 weeks of age, were anesthetized with isoflurane and injected intratracheally on day 0 with bleomycin sulfate at a dose of 3 U / kg in 50 μl of 0.9% saline (NS) or NS alone. Mice were then injected with a bolus dose of 200 μl of MEx (5 × 10 6 MSC-generated EVs, treatment group), received human dermal fibroblast-derived exosomes (FEx); 6 EVs generated by human dermal fibroblasts; first control group) or OptiPrep™ (iodixanol, IDX, diluted 1:9); (vehicle, second control group) or NS via tail vein injection on days 0 and 7.
[0095] After bleomycin treatment at the designated time points, mice were euthanized with an intraperitoneal injection of pentobarbital, and the hearts were perfused with phosphate-buffered saline (PBS, Invitrogen) through the right ventricle.
[0096] For histological analysis, the trachea was cannulated and the lungs inflated with 4% paraformaldehyde. The right lung was embedded in paraffin and sectioned for hematoxylin and eosin or Masson's trichrome staining. The left lung was either flash frozen in liquid nitrogen and used for RNA and protein isolation or used fresh for collagen quantification or cytometric analysis. Randomly selected areas (10–15 fields) from 5-μm-thick lung sections were acquired at magnifications of x100 and x200 using a Nikon Eclipse 80i microscope (Nikon, Tokyo, Japan). Large airways and blood vessels were not imaged. For histological quantification, the Ashcroft score was used in a blinded manner. A score of 0–1 indicated no fibrosis, a score of 2–3 indicated minimal fibrosis, a score of 4–5 indicated moderate fibrosis, and a score of 6–8 indicated severe fibrosis ( 23 ).
[0097] BMDMo were isolated as previously described ( 11 ). Cell suspensions were used for cytometric analysis, and adherent cells cultured after 3 days were used for adoptive transfer experiments (further details can be found in the online supplementary material).
[0098] Exosome isolation and purification Exosome isolation, purification, and characterization were performed using OptiPrep™ (iodixanol; IDX) cushion density buoyancy as previously described. (11) Briefly, concentrated conditioned medium from bone marrow MSCs or human dermal fibroblasts (HDFs) was floated on top of an IDX cushion and centrifuged at 100,000xg for 3.5 h at 4°C.
[0099] statistics Data between different groups were compared using ANOVA with Fisher's LSD test post-hoc analysis in GraphPad Prism (v6.0; GraphPad, CA, US). Flow cytometry data analysis was performed with FlowJo software v10.2 (TreeStar, OR, US). mRNA levels were assessed by RT-qPCR and expressed relative to endogenous control. For statistical analysis, ΔCT was used. Data are presented as mean ± standard error of the mean (SEM). Significance was determined with respect to a p<0.05 threshold unless otherwise stated. A minimum of five animals in each group was used, yielding a power of >90% at an α level of 5%.
[0100] result MEx administration during early inflammation prevents pulmonary fibrosis A well-established bleomycin lung injury model was used for pulmonary fibrosis characterized by an inflammatory phase (days 0 to 8) followed by a fibrotic phase (days 9 to 32) ( 24 ).
[0101] To investigate the role of MEx in preventing pulmonary fibrosis, 10- to 14-week-old mice received intratracheal bleomycin (3 U / kg) or NS (vehicle, control) on day 0, followed by a bolus dose of intravenous (IV) MEx via the tail vein. Mice were sacrificed on day 14 and lungs were assessed for quantification of fibrosis and collagen content (Figure 1A). Bleomycin increased the Ashcroft score by more than three-fold compared to control mice. There was a significant reduction in fibrosis scores in MEx-treated mice (Bleo+MEx) compared to the bleomycin group (Bleo+NS, Figures 1B and 1C). Similarly, the increase in collagen deposition induced by bleomycin was substantially reduced in Bleo+MEx mice (Figure 1D). To confirm that the therapeutic effect was specific to MEx, bleomycin-exposed mice were injected with fibroblast exosomes (Bleo+FEx) and similarly with iodixanol (Bleo+IDX). No improvement in fibrosis or collagen deposition was observed in the aforementioned groups. To exclude possible lung structural changes with MEx treatment, control mice were injected with MEx. The treatment was well tolerated in mice, and lung collagen content and histology were similar to control mice receiving NS (Figures 1B to 1D).
[0102] These results show that a single dose of IVMEx at the onset of the inflammatory phase prevents fibrosis, an effect that is specific to MSC exosomes, as fibroblast-derived exosomes [and exosome isolation medium (iodixanol)] did not prevent pulmonary fibrosis.
[0103] MEx treatment of inflammation reverses pulmonary fibrosis To assess the effect of MEx at later stages of inflammation, mice were injected with MEx 7 days after bleomycin administration (Figure 7A). Similar to what was observed in the preventive therapy experiment (MEX injection on day 0), administration of MEx at the inflammatory stage led to an improvement in fibrosis scores and a statistically significant reduction in collagen deposition (Figures 7B, 7C, and 7D). Thus, MEx treatment ameliorates fibrosis even when administered at the end of inflammation.
[0104] MEx modulates alveolar macrophage phenotype and blunted inflammation To investigate the mechanism of action of MEx in the bleomycin lung injury model, prophylactic therapy experiments (MEx injection on day 0) were performed.
[0105] Monocyte-derived macrophages are involved in the development and progression of fibrosis (20, 21), therefore, the role of MEx in modulating inflammation through the regulation of inflammatory and profibrotic macrophage phenotypes was evaluated. Gene expression analysis in whole lungs 7 or 14 days after administration of bleomycin showed increased expression levels of macrophage inflammatory markers Ccl-2 and arginase-1 (Arg1), while their mRNA levels were comparable to those observed in control lungs with MEx treatment. Interleukin-6 mRNA levels showed a similar trend to those of Ccl-2 and Arg1, although the differences did not reach statistical significance between groups. Furthermore, TGF-β expression was similar at both time points in all three experimental groups (Figures 2A and 2B). Immunoluminescence (IF) staining of lung tissue sections with CD206 and Arg1 antibodies, macrophage markers of M2-like activation, showed increased IF intensity in mice that received bleomycin, but remained similar to control levels when mice were treated with MEx (Figures 2C and 2D). Flow cytometry analysis of whole lungs also demonstrated that CD206-expressing alveolar macrophages (AMs) (CD45 +ve CD11b -ve CD11c +ve CD206 +veThe results showed an increase in CD206-expressing AMs (Figure 2E). Despite the lower number of CD206-expressing AMs with MEx treatment, the levels did not reach statistical significance (Figure 2E). The above results reveal that MEx exerts an anti-inflammatory effect through modulation of AM phenotype in the lung.
[0106] MEx restores alveolar macrophage and regulatory monocyte populations in the lung To investigate the dynamic changes in immune cell populations following bleomycin injury and MEx treatment, cytometric analysis was performed in whole lungs on days 7 and 14 after bleomycin administration. AM counts (CD45 +ve CD11b -ve CD11c +ve A decrease in Ly6C high classical or inflammatory monocytes (CD45 +ve CD11b +ve MHCII -ve Ly6C high CCR-2 +ve The increase in the number of AMs (cells) was associated with an increase in the number of AMs (Figure 3B). However, at day 14, the percentage of AMs increased after bleomycin instillation (Figure 3C), while the number of classical monocytes was reduced (Figure 3D). MEx treatment restored the infiltration of AMs and monocyte populations to levels similar to those of the control group at both days 7 and 14. These results indicate that after lung injury, MEx can restore the homeostatic balance between AMs and recruited monocyte populations, similar to the levels and phenotype seen in control mice.
[0107] MEx can modulate monocyte phenotype in the bone marrow Given the findings of increased inflammatory monocytes in the lungs of bleomycin-exposed mice, and the fact that monocyte development occurs in the bone marrow (BM) following recovery to normal levels after MEx treatment (25), it was proposed that MEx may exert an immunomodulatory effect by modifying monocyte phenotype in the BM. To answer this question, the possibility of MEx to infiltrate the BM was first investigated. Dye-labeled EVs were injected intravenously into control mice, and animals were sacrificed at 2, 4, 8, and 24 h post-injection. Dapi staining of BM cytospins revealed the presence of EVs in the BM up to 8 h post-injection (Figure 9, images represent 2 h post-injection, further time points are not shown).
[0108] The systemic effects of MEx were then investigated by focusing on the characteristics of myeloid cells in the BM. Interestingly, flow cytometric analysis of myeloid cells isolated from the BM of control, bleomycin, and MEx-treated mice during the active inflammatory phase (day 7) showed changes similar to those observed in the lungs. CD45 +ve Despite comparable numbers of cells (data not shown), the number of regulatory monocytes (Cd45 +ve CD11b high MHCII -ve Ly6C low CCR-2 -ve The number of monocytes (cells) was less than half in bleomycin-exposed mice compared to MEx-treated and control mice (14.18% vs. 27.57% and 32.3% ± 5.7, respectively, Figure 3E). In contrast, the monocyte population in the bleomycin-exposed group consisted of approximately 70% (67.8% ± 1.7) classical monocytes compared to approximately 50-60% in MEx-treated and control mice (57.5% ± 3.9 and 50.1% ± 3.2, respectively, Figure 3F). These results suggest that in the presence of organ injury, MEx exerts an immunomodulatory effect by altering the monocyte population from a proinflammatory to a regulatory phenotype in the bone marrow.
[0109] The immunomodulatory effects of MEx in BMDMo are sufficient to prevent pulmonary fibrosis Given the increase in BM regulatory monocytes after MEx treatment, it was hypothesized that the immunomodulatory effects of MEx on bone marrow monocytes may be sufficient to prevent fibrosis, with further changes in the lung being the result of altered BM monocyte subpopulations.
[0110] To test this hypothesis, the effect of ex vivo treated BMDMo in preventing fibrosis was investigated. Adoptive transfer experiments were performed in which primary Mo were isolated from wild-type FVB mice and cultured for 3 days. Cells were treated with MEx (BMDMo+MEx) or medium alone (BMDMo+medium) on days 1 and 2 (Figure 4A). On day 3, more than 90% of bone marrow cells were CD45 +ve CD11b +ve Monocytes were then labeled with Dil (a luminescent lipophilic dye) and adoptively transferred intravenously into C57BL / 6 mice on days 0 and 3 after instillation of bleomycin. Mice were sacrificed on day 14, and lungs were assessed for histology and collagen content. Results were compared to mice receiving bleomycin with NS injection (bleomycin). 14 days after administration of bleomycin, Dil-labeled monocytes were identified in the lungs (Figure 4C). Interestingly, less fibrosis was detected in mice receiving BMDMo+MEx compared to mice receiving bleomycin and BMDMo+medium, both by histological quantification and collagen assay. Surprisingly, minimal improvement in fibrosis scores in histology and statistically non-significant collagen deposition was detected in the BMDMo+medium-treated group compared to bleomycin-exposed mice (Figures 4D, 4E, and 4F). To investigate whether the antifibrotic effect was instead due to resident AM, MEx-treated AM (AM+MEx) were administered intratracheally after bleomycin instillation (details are provided in Supplementary Methods). No improvement in fibrosis was detected in mice receiving pretreated AM compared to the bleomycin group (Figure 4E).
[0111] These data strongly suggest that treatment of BMDMo with MEx promotes a regulatory phenotype that, by itself, ameliorates fibrosis. This further confirms that the therapeutic impact of MEx is not limited to the lung and that MEx exerts a systemic anti-inflammatory effect by modulating myelomonocytic phenotype, leading to attenuated inflammation and prevention of fibrosis in injured lungs.
[0112] MEx treatment reduces apoptosis Alveolar epithelial cell apoptosis (AEC) has been described as a trigger for profibrotic signals in injured lungs (26, 27). To explore further mechanisms by which MEx protects against lung injury, the potential role of MEx in reducing apoptosis after bleomycin injury was investigated. The extent of lung apoptosis was assessed using Tunel staining in lung sections from control, bleomycin, and MEx treated mice. While an increase in apoptosis was seen in the bleomycin exposed group, apoptosis levels were similar in bleo+MEx and control mice (Figure 5A, 5B). In addition, Annexin V / PI staining was performed in whole lungs on day 14. There was again an increase in apoptosis (Annexin V+ / PI-) present in bleomycin compared to control and MEx treated mice (Figure 5C).
[0113] Furthermore, the direct anti-apoptotic effect of MEx in human alveolar epithelial cells (A549, AEC) was assessed. An in vitro assay was designed to induce epithelial cell apoptosis by treating A549 cells with bleomycin. A group of bleomycin-exposed AECs was treated with MEx for 24 hours, and changes in apoptosis were determined by the activity of caspases 3 and 7 using the Caspase-Glo® 3 / 7 luminescent assay. There was an increase in apoptosis in the bleomycin group, which was abolished in MEx-treated cells (Figure 5D). The above findings support the important anti-fibrotic effect of MEx in vitro and in vivo.
[0114] Consideration This study shows that a single IV dose of human bone marrow-derived MEx, either at the initiation or end of the inflammatory phase of bleomycin-induced lung injury, significantly prevents fibrosis and restores lung architecture. MEx treatment not only blunted inflammation in the lung, but also restored AMs and recruited monocyte numbers to levels similar to control mice. The previous observations and the fact that monocyte development occurs in the bone marrow (BM) led us to investigate the upstream immunomodulatory effects of MEx by investigating the properties of BM myeloid cells. In addition to visualizing labeled MEx in the BM, flow cytometric analysis of BM myeloid cells revealed that in MEx-treated mice, proinflammatory (Ly6ChighCCR-2 +ve ) to regulatory (Ly6C low CCR-2 -ve ) phenotype.
[0115] Interestingly, using novel MEx-pretreated BMDMo adoptive transfer experiments, it was shown that the immunomodulatory effects of MEx on BM monocytes were at least partially sufficient to explain their protective effects in the lung. Finally, other potential mechanisms in the protection against pulmonary fibrosis were explored, and a reduction in apoptosis was found in the lungs of MEx-treated mice. Furthermore, in vitro experiments revealed that MEx exerts its antiapoptotic effects by targeting alveolar epithelial cells.
[0116] To rationalize the cytometry results at different time points (days 7 and 14) in bleomycin-exposed mice, previous findings were taken into account that recruited inflammatory (Ly6C high) monocytes and monocyte-derived alternatively activated macrophages (M2-like) are associated with the development and progression of fibrosis (20–22, 28–31). In addition, these results revealed that the increase in inflammatory monocytes after bleomycin lung injury begins in the BM. It is believed that the bleomycin-induced loss of resident AMs signals BM stem cells to increase their differentiation into proinflammatory monocytes, and these cells then assemble in the lung during the inflammatory phase (as seen at day 7 in our model). These classical monocytes differentiate into M2-like AMs at later stages of injury, providing a profibrotic environment that further exacerbates the fibrotic response. This explains the increase in AMs and their inflammatory markers at day 14.
[0117] MSC-EVs can repopulate the BM of irradiated mice with Sca-1 positive and c-kit low positive stem cells (32). They have also been shown to modulate monocyte trafficking in a model of myocarditis (33). In the presence of organ injury, MSC-EVs may reprogram bone marrow stem cells to differentiate into a regulatory phenotype. As a result, there was an increase in regulatory monocytes in the BM and a reduction in inflammatory monocytes in the lung, and therefore less differentiation into profibrotic macrophages. The prevention of fibrosis with adoptive transfer of MEx-treated BMDMo strongly suggests that alteration of the BM monocyte phenotype is a mechanistic explanation for the subsequent antifibrotic effect of MEx in the lung. This effect was not reproduced by intratracheal injection of MEx-treated AM. In a recent study by Morrison and colleagues, intratracheal administration of MSC-EV-treated AM in an LPS-induced acute lung injury model reduced inflammation (17). While these results are also consistent with an immunomodulatory effect of MSC-EVs on macrophages, the lack of amelioration of fibrosis after AM transfer in this experiment may be due to differences in disease models and therefore different underlying pathophysiology. Van de Laar and colleagues demonstrated that both mature AMs and BMDMo have the capacity to colonize empty AM niches and develop into functional tissue-resident macrophages (34). It is possible that the absence of an empty AM niche at the onset of inflammation (days 0 to 3 of the adoptive transfer experiment) did not allow sufficient colonization by the transplanted AMs.
[0118] Finally, using various in vivo methods, it has been shown that in addition to immunomodulation, MEx can also potentially prevent fibrosis through the reduction of apoptosis. Furthermore, the in vitro assays described herein suggest that this effect is produced by targeting alveolar epithelial cells.
[0119] This study has limitations. The current therapeutic dose was estimated based on previous experiments. Therefore, future studies should be conducted to investigate the dose-response.
[0120] In this study, we investigated the effects of MSC exosomes in an experimental model of IPF. The findings provide new insights into the systemic inflammatory response after bleomycin lung injury and into the alteration of monocyte phenotype in the bone marrow. In addition, this study reveals a new mechanistic explanation for the immunomodulatory effects of MSC exosomes and their source of action. MSC exosomes are believed to be a promising cell-free therapy for the treatment of fibrotic lung diseases when administered early in the disease course.
[0121] Supplementary Methods Cell isolation and culture Human bone marrow mesenchymal stem cells (BMSCs) were obtained from RoosterBio (RoosterBio, MD, US). Human foreskin (dermal) fibroblasts (HDFs) were established by tissue explant method (36). BMSCs and HDFs were cultured and expanded and further characterized as previously described (37). A549 alveolar epithelial cells (ATCC) were cultured in F-12K medium (Thermo Fisher Scientific, Inc., Waltham, MA).
[0122] Transmission electron microscope (TEM) Aliquots of 5–10 μl of extracellular vesicle (EV) preparations were adsorbed onto formvar / carbon-coated grids (Electron Microscopy Sciences, PA, US) for 15 s. Samples were stained with 2% uranyl acetate after removal of excess liquid with Whatman Grade 1 filter paper (Sigma). EVs were then observed in a JEOL 1200EX transmission electron microscope (TEM) and images were recorded with an AMT 2k CCD camera.
[0123] Nanoparticle tracking analysis Exosome size and concentration distributions were determined using nanoparticle tracking analysis (NTA, NanoSight LM10 system, Malvern instruments, MA, US) as previously described ( 37 ).
[0124] Western blot analysis Proteins in exosome preparations were separated on 4–20% polyacrylamide gels (Bio-Rad, Hercules, CA) followed by transfer to 0.45 μm PVDF membranes (Millipore, MA, US). Rabbit polyclonal anti-flotillin-1 and anti-CD63 antibodies (Santa Cruz Biotech, CA, US), and mouse monoclonal anti-Alix antibody (Santa Cruz Biotech, CA, US) were used according to the manufacturer's recommended dilutions.
[0125] EV dosing EV preparations were 5 x 10 6 The dose was diluted in PBS to correspond to a cell equivalent, which was estimated based on previous dose calculations in newborn mice with corresponding NTA and protein concentrations ( 37 ).
[0126] Immunoluminescence staining Lung tissue sections were deparaffinized with xylene and rehydrated. Tissue slides were treated with 10 mM citrate buffer and blocked with serum and BSA for 20 min. Samples were then incubated overnight at 40°C with the indicated primary antibodies: Arginase 1 (Santa Cruz Biotech, CA, US); CD206 (Santa Cruz Biotech, CA, US), and then further incubated with secondary antibodies (Life technologies, MA, US) for 20 min, followed by nuclear staining with DAPI for 10 min.
[0127] Arginase 1 and CD206 positive cells were imaged using a Nikon Eclipse 80i microscope (Nikon, Tokyo, Japan). 10–15 random images were analyzed using Image J software.
[0128] Mean luminescence intensity (MFI) was calculated using the following formula: MFI = integrated density - (area of selected cells * average luminescence of background reading).
[0129] Sircol collagen assay The left lung was used for collagen quantification according to the manufacturer's protocol (Biocolor, Life Science Assays). Briefly, left lung homogenates were shaken overnight at 4° in 5 ml of 0.5 M acetic acid with 0.6% pepsin. 1 ml of dye reagent was added to 100 μl of clear supernatant and samples were vortexed for 30 min. The remaining pellet was washed with acid salt wash buffer to remove unbound collagen and pH was normalized with alkalinization buffer. Absorbance was measured at a wavelength of 550 nm in a microplate reader. Measured collagen content was compared to a standard curve and expressed as mg / ml of left lung homogenate.
[0130] Cytometric analysis of whole lung and bone marrow in mice Lung macrophage populations were assessed by flow cytometry as previously described (38). Lungs were harvested on days 7 and 14. The left lung was cut into small pieces and digested in 5 ml of digestion buffer consisting of RPMI-1640 (Invitrogen, CA, US), collagenase IV (1.6 mg / ml); and DNAse 1 (50 units / ml) (both from Worthington Biochemical Corp, NJ, US). Lungs were shaken for 30 min at 37°C, and red blood cells (RBCs) were lysed using RBC lysis buffer (Roche, IN, US). Homogenized lungs were passed through a 40 μm cell strainer (Corning, MA, US) to obtain a single cell suspension.
[0131] For assessment of alveolar macrophage and monocyte populations, cell suspensions were stained with the following antibodies: PE / Cy7-conjugated anti-mouse CD45, FITC-conjugated anti-mouse CD11b, PerCPCy5.5-conjugated anti-mouse CD11c, BV421-conjugated anti-mouse CD206, BV605-conjugated anti-mouse MHCII, BV510-conjugated anti-mouse Ly6C, and Alexa647-conjugated anti-mouse CCR-2.
[0132] For the assessment of bone marrow-derived monocytes (BMDMo), cells freshly flushed from femurs and tibias of adult mice were stained with PE / Cy7-conjugated anti-mouse CD45, FITC-conjugated anti-mouse CD11b, BV605-conjugated anti-mouse MHCII, BV510-conjugated anti-mouse Ly6C, and Alexa647-conjugated anti-mouse CCR-2 (all antibodies were obtained from Biolegend, CA, US). Similar staining was performed on BMDMo harvested after 3 h of in vitro culture.
[0133] Compensation was adjusted accordingly and supported by UltraComp ebeads (Affymetrix, CA, US). Fluorescence-minus-one controls were used accordingly. Cell populations were identified according to the gating strategy illustrated in Figure 8 and recorded as a percentage of the total cell population.
[0134] Reverse transcription-polymerase chain reaction analysis Total RNA was extracted from the left lung using TRIZOL® (Thermo Fisher Scientific, Inc., Waltham, MA) according to the manufacturer's instructions. TaqMan® primers used in the PCR reactions, including Ccl2, Il6, TGF-β, and Arginase 1, were obtained from Invitrogen.
[0135] Nuclear pore protein 133 served as an internal control. Analysis of fold changes compared with control mice was performed as previously described ( 39 ).
[0136] Annexin V / PI apoptosis assay, Tunel staining and caspase 3 / 7 assay Annexin V staining kit (Sigma-Aldrich, MO, US) was used to assess apoptosis in whole lungs. Single cell suspensions were obtained from the left lung as described above. Cells were then suspended in 1x binding buffer, stained with FITC-conjugated Annexin V and PI antibodies for 10 min, and immediately assessed by flow cytometry.
[0137] Apoptosis was assessed in paraffin-embedded lung tissue using the TACS® TdT in situ-fluorescein Tunel Assay (R&D systems, MN, US) according to the manufacturer's protocol. Briefly, deparaffinized lung sections were permeabilized with Cytonin for 1 hour and labeled with a combination of manganese cations, TdT dNTP Mix, and TdT enzyme, followed by incubation with Strep-Fluor solution for 20 minutes. Luminescence imaging and quantification were performed as described above.
[0138] Caspase 3 / 7 assay (G8090, Promega) was performed according to the manufacturer's instructions. 4 A549 alveolar epithelial cells were plated overnight in a 96-well plate. The cells were treated with 0.1 μg / well bleomycin sulfate or medium alone for 24 hours (8 wells per group). After this, 1 μl / well of MEx (approximately 2×10 4 This was followed by a 24-hour treatment with 100 μl of EVs (corresponding to EVs generated by MSCs). Bleomycin-treated cells treated with medium alone served as a control. All experiments were performed in serum-free medium. On day 3, cells were washed with PBS and 50 μl of fresh medium was added to each well. To measure caspase 3 / 7 activity, 50 μL of Caspase Glo3 / 7 reagent was added to each well for 2 hours at room temperature and the plate was left on a plate shaker. Luminescence was measured using a VICTOR multilabel plate reader. Background luminescence (measured in cell-free wells) was subtracted from each reading.
[0139] Adoptive transfer of MEx-treated bone marrow-derived monocytes BMDMo were isolated from 6-8 week old FVB by flushing the femurs and tibiae and culturing the cells for 3 days in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FBS and containing 30% v / v L929-conditioned medium (as a source of macrophage colony stimulating factor; M-CSF). Each plate was cultured with 1x10 6 MEx generated from MSCs or medium alone. Cells were harvested on day 3, washed twice with PBS, and then stained with Dil according to the manufacturer's protocol (Life technologies). BMDMo were then administered via tail vein injection at a 1:1 ratio on days 0 and 3 after intratracheal instillation of bleomycin (BMDMo isolated from one mouse was injected into the experimental mice).
[0140] Adoptive transfer of alveolar macrophages from MEx-treated mice Six- to eight-week-old FVB mice were euthanized by ip pentobarbital injection, and the anterior wall of the trachea was cannulated with a 21-gauge needle and secured with a string.
[0141] Bronchoalveolar lavage fluid (BALF) was collected with 5 flushes of 0.6 ml of sterile HBSS (supplemented with 0.5 mM EDTA and 1 mM HEPES) using a 1 ml syringe. BALF was centrifuged at 400 x g for 5 min and the supernatant was aspirated. Mouse AM were resuspended in fresh RPMI medium supplemented with 1% penicillin / streptomycin and 10% FBS and plated at 1x10 per well in 35 mm plates. 6 Each plate was seeded at a seeding density of 1x10 6 The mice were treated overnight with MEx produced from 100% bleomycin-treated mice. The cells were harvested 24 hours later, washed twice with PBS, stained with Dil, and resuspended in 50 μl of PBS. AM were administered intratracheally at a 1:1 ratio (AM isolated from one mouse was administered to the experimental mouse) on days 0 and 3 after bleomycin instillation.
[0142] Ex vivo EV labeling and bone marrow cytospins EVs were pelleted from the enriched conditioned medium of bone marrow MSCs at 100,000g for 70 min. EV protein concentration was determined using the Micro BCA Protein Assay Kit (Thermo Fisher Scientific, Inc., Waltham, MA). EVs were labeled by ExoGlow-Membrane™ EV labeling kit (System biosciences, CA, USA) according to the manufacture protocol. Briefly, 50–100 μg of EVs were added to a mixture of reaction buffer and labeling dye and incubated at room temperature for 30 min. Free unlabeled dye was removed after a second ultracentrifugation at 100,000g for 70 min. 1 × 10 6 EVs generated by equivalent amounts of MSCs were diluted in 200 μl of PBS and injected into C57BL / 6 mice via tail vein injection. 200 μl of stained EV-free SN or diluent-free dye were used as controls.
[0143] Mice were sacrificed at 2, 4, 8, and 24 hours post-injection. Femurs were flushed with PBS, and cell suspensions were cytocentrifuged at 300 g for 5 min using a Shandon Cytospin 4 (Thermo Fisher Scientific, Inc., Waltham, MA). Slides were air-dried, fixed in 4% paraformaldehyde, and counterstained with Dapi. Images were obtained using a Nikon Eclipse 80i microscope (Nikon, Tokyo, Japan).
[0144] References 1. Kaunisto J, Salomaa ER, Hodgson U, Kaarteenaho R, Myllarniemi M. Idiopathic pulmonary fibrosis - a systematic review on methodology for the collection of epidemiological data. BMC Pulmonary Medicine. 2013;13:1. 2. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol. 2013;5:483-92. 3. Mylla M, Kaarteenaho R. Pharmacological treatment of idiopathic pulmonary fibrosis A preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. European Clinical Respiratory Journal. 2015;2:1-10. 4. Harari S, Caminati A, Madotto F, Conti S, Cesana G. Epidemiology, survival, incidence and prevalence of idiopathic pulmonary fibrosis in the USA and Canada. Eur Respir J. 2017;49(1).
[0145] 5. Cottin V. The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respiratory research. 2013;14 Suppl 1:S5. 6. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760-9. 7. Matthay MA, Anversa P, Bhattacharya J, Burnett BK, Chapman HA, Hare JM, et al. Cell Therapy for Lung Diseases. Report from an NIH-NHLBI Workshop, November 13-14, 2012. American Journal of Respiratory and Critical Care Medicine2013. p. 370-5. 8. Ghadiri M, Young PM, Traini D. Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease. Expert Opinion on Biological Therapy. 2016;16:375-87. 9. Toonkel RL, Hare JM, Matthay MA, Glassberg MK. Mesenchymal stem cells and idiopathic pulmonary fibrosis potential for clinical testing. American Journal of Respiratory and Critical Care Medicine. 2013;188:133-40.
[0146] 10. Srour N, Thebaud B. Mesenchymal Stromal Cells in Animal Bleomycin Pulmonary Fibrosis Models: A Systematic Review. Stem Cells Transl Med. 2015;4(12):1500-10. 11. Willis GR, Fernandez-Gonzalez A, Anastas J, Vitali SH, Liu X, Ericsson M, et al. Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation. Am J Respir Crit Care Med. 2018;197(1):104-16. 12. Willis GR, Kourembanas S, Mitsialis SA. Toward Exosome-Based Therapeutics: Isolation, Heterogeneity, and Fit-for-Purpose Potency. Front Cardiovasc Med. 2017;4:63. 13. Cruz FF, Borg ZD, Goodwin M, Sokocevic D, Wagner DE, Coffey A, et al. Systemic Administration of Human Bone Marrow-Derived Mesenchymal Stromal Cell Extracellular Vesicles Ameliorates Aspergillus Hyphal Extract-Induced Allergic Airway Inflammation in Immunocompetent Mice. Stem cells translational medicine. 2015;4:1302-16. 14. Lee C, Mitsialis SA, Aslam M, Vitali SH, Vergadi E, Konstantinou G, et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia- induced pulmonary hypertension. Circulation. 2012;126(22):2601-11.
[0147] 15. Sdrimas K, Kourembanas S. MSC Microvesicles for the Treatment of Lung Disease: A New Paradigm for Cell-Free Therapy. Antioxidants & redox signaling. 2014;21:1905-15. 16. Heldring N, Mager I, Wood M, Le Blanc K, El Andaloussi S. Therapeutic potential of multipotent mesenchymal stromal cells and their extracellular vesicles. Human gene therapy. 2015;26:506-17. 17. Morrison TJ, Jackson MV, Cunningham EK, Kissenpfennig A, McAuley DF, O'Kane CM, et al. Mesenchymal Stromal Cells Modulate Macrophages in Clinically Relevant Lung Injury Models by Extracellular Vesicle Mitochondrial Transfer. Am J Respir Crit Care Med. 2017;196(10):1275-86. 18. Phinney DG, Di Giuseppe M, Njah J, Sala E, Shiva S, St Croix CM, et al. Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. Nat Commun. 2015;6:8472. 19. Burrello J, Monticone S, Gai C, Gomez Y, Kholia S, Camussi G. Stem Cell-1. Burrello, J. et al. Stem Cell-Derived Extracellular Vesicles and Immune-Modulation. Front. Cell Dev. Biol. 4, 1-10 (2016).Derived Extracellular Vesicles and Immune- Modulation. Frontiers in Cell and Developmental Biology. 2016;4:1-10.
[0148] 20. Gibbons MA, MacKinnon AC, Ramachandran P, Dhaliwal K, Duffin R, Phythian- Adams AT, et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. American Journal of Respiratory and Critical Care Medicine. 2011;184:569-81. 21. Misharin AV, Morales-Nebreda L, Reyfman PA, Cuda CM, Walter JM, McQuattie- Pimentel AC, et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. The Journal of experimental medicine. 2017;214:2387-404. 22. McCubbrey AL, Barthel L, Mohning MP, Redente EF, Mould KJ, Thomas SM, et al. Deletion of c-FLIP from CD11b(hi) Macrophages Prevents Development of Bleomycin-induced Lung Fibrosis. Am J Respir Cell Mol Biol. 2018;58(1):66-78. 23. Hubner RH, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques. 2008;44(4):507-11, 14-7. 24. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):362-82.
[0149] 25. Zimmermann HW, Trautwein C, Tacke F. Functional role of monocytes and macrophages for the inflammatory response in acute liver injury. Front Physiol. 2012;3:56. 26. Cheresh P, Kim SJ, Tulasiram S, Kamp DW. Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta. 2013;1832(7):1028-40. 27. Kim SJ, Cheresh P, Jablonski RP, Williams DB, Kamp DW. The Role of Mitochondrial DNA in Mediating Alveolar Epithelial Cell Apoptosis and Pulmonary Fibrosis. Int J Mol Sci. 2015;16(9):21486-519. 28. Bellon T, Martinez V, Lucendo B, del Peso G, Castro MJ, Aroeira LS, et al. Alternative activation of macrophages in human peritoneum: implications for peritoneal fibrosis. Nephrol Dial Transplant. 2011;26(9):2995-3005. 29. Braga TT, Agudelo JSH, Camara NOS. Macrophages during the fibrotic process: M2 as friend and foe. Frontiers in Immunology. 2015;6:1-8.
[0150] 30. Kolahian S, Fernandez IE, Eickelberg O, Hartl D. Immune Mechanisms in Pulmonary Fibrosis. 2016;55:309-22. 31. Mora AL, Torres-Gonzalez E, Rojas M, Corredor C, Ritzenthaler J, Xu J, et al. Activation of alveolar macrophages via the alternative pathway in herpesvirus-induced lung fibrosis. Am J Respir Cell Mol Biol. 2006;35(4):466-73. 32. Schoefinius JS, Brunswig-Spickenheier B, Speiseder T, Krebs S, Just U, Lange 33. C. Mesenchymal Stromal Cell-Derived Extracellular Vesicles Provide Long-Term Survival After Total Body Irradiation Without Additional Hematopoietic Stem Cell Support. Stem Cells. 2017;35(12):2379-89. 34. Miteva K, Pappritz K, El-Shafeey M, Dong F, Ringe J, Tschope C, et al. Mesenchymal Stromal Cells Modulate Monocytes Trafficking in Coxsackievirus B3- Induced Myocarditis. Stem Cells Transl Med. 2017;6(4):1249-61.
[0151] 35. van de Laar L, Saelens W, De Prijck S, Martens L, Scott CL, Van Isterdael G, et al. Yolk Sac Macrophages, Fetal Liver, and Adult Monocytes Can Colonize an Empty Niche and Develop into Functional Tissue-Resident Macrophages. Immunity. 2016;44:755-68. 36. Nichols WW, Murphy DG, Cristofalo VJ, Toji LH, Greene AE, Dwight SA. Characterization of a new human diploid cell strain, IMR-90. Science. 1977;196(4285):60-3. 37. Willis GR, Fernandez-Gonzalez A, Anastas J, Vitali SH, Liu X, Ericsson M, et al. Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation. Am J Respir Crit Care Med. 2018;197(1):104-16. 38. Misharin AV, Morales-Nebreda L, Mutlu GM, Budinger GR, Perlman H. Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung. Am J Respir Cell Mol Biol. 2013;49(4):503-10. 39. Lee C, Mitsialis SA, Aslam M, Vitali SH, Vergadi E, Konstantinou G, et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation. 2012;126(22):2601-11.
[0152] All publications, patents, patent applications, publications, and database entries (e.g., sequence database entries) mentioned herein, for example in the Background, Overview, Detailed Description, Examples, and / or References sections, are incorporated herein by reference in their entirety, as if each individual publication, patent, patent application, publication, and database entry was specifically and individually incorporated herein by reference. In the case of conflict, the present application, including definitions herein, will control.
[0153] Equivalents and Scope Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the embodiments described herein. The scope of the present disclosure is not limited to the above description, but rather is set forth in the appended claims.
[0154] Articles such as "a," "an," and "the" may mean one or more, unless indicated to the contrary or clear from the context. A claim or description including "or" between two or more members of a group is deemed to be satisfied when one, more than one, or all of the group members are present, unless indicated to the contrary or clear from the context. The present disclosure of groups including "or" between two or more group members provides embodiments in which exactly one member of the group is present, embodiments in which more than one member of the group is present, and embodiments in which all of the members of the group are present. For the sake of brevity, these embodiments have not been individually described herein, but it will be understood that each of these embodiments is provided herein and may be specifically claimed or disclaimed.
[0155] It should be understood that the present disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, or descriptive terms from one or more of the claims or from one or more relevant parts of the description are introduced into another claim. For example, a claim that is dependent on another claim can be amended to encompass one or more limitations found in any other claim that is dependent on the same base claim. Furthermore, when a claim describes a composition, it should be understood that the claim includes any method of making or using the composition according to any of the methods of making or using disclosed herein, or according to any method known in the art, unless otherwise stated or unless it would be obvious to a person skilled in the art that an inconsistency or inconsistency would occur.
[0156] When elements are presented as lists, for example in Markush group format, it is understood that all possible subgroups of elements are also disclosed, and any element or subgroup of elements may be removed from the group. It is also noted that the term "comprising" is intended to be open, permitting the inclusion of additional elements or steps. In general, when an aspect, article, or method is described as comprising a particular element, feature, or step, it should be understood that an aspect, article, or method consisting of or consisting essentially of such element, feature, or step is also provided. Although for brevity, the aspects are not individually described herein, it will be understood that each of these aspects is provided herein and may be specifically claimed or disclaimed.
[0157] Where ranges are given, the endpoints are included. Furthermore, unless otherwise stated or otherwise evident from the context and / or the understanding of a person skilled in the art, it should be understood that values expressed as ranges can take any specific value within the stated range in some embodiments (to the tenth of the unit of the lower limit of the range, unless otherwise clearly indicated by the context). For the sake of brevity, each range value is not individually described herein, but it will be understood that each of these values is provided herein and may be specifically claimed or disclaimed. Furthermore, unless otherwise stated or otherwise evident from the context and / or the understanding of a person skilled in the art, it should be understood that values expressed as ranges can take any subrange within the given range (the endpoint of the subrange is expressed to the same precision as the unit of the lower limit of the range).
[0158] When a website is provided, the URL addresses are provided as code that cannot be executed by the browser, and the periods in each web address are enclosed in parentheses. The actual web address does not include the parentheses.
[0159] Furthermore, it should be understood that any particular aspect of the present disclosure may be expressly excluded from any one or more of the claims. Where ranges are given, any value within the range may be expressly excluded from any one or more of the claims. Any aspect, element, feature, use, or aspect of the compositions and / or methods of the present disclosure may be excluded from any one or more of the claims. For the sake of brevity, all of the aspects in which one or more elements, features, purposes, or aspects are excluded are not expressly set forth herein.
Claims
1. 1. A method of modulating a monocyte phenotype, comprising contacting a monocyte with isolated mesenchymal stem cell (MSC) exosomes.
2. The method of claim 1 , wherein the monocytes are from bone marrow.
3. 3. The method of claim 1 or claim 2, wherein the isolated MSC exosomes are isolated from MSC conditioned medium.
4. The method of any one of claims 1 to 3, wherein the MSCs are from Wharton's jelly, bone marrow, or adipose tissue.
5. The method of any one of claims 1 to 4, wherein the isolated MSC exosomes are substantially free of protein contaminants.
6. The method of any one of claims 1 to 5, wherein the isolated MSC exosomes have a diameter of about 50 to 150 nm.
7. The method of any one of claims 1 to 6, wherein the contacting is in vitro.
8. The method of any one of claims 1 to 6, wherein the contacting is ex vivo.
9. The method of any one of claims 1 to 6, wherein the contacting is in vivo.
10. The method of any one of claims 1 to 9, wherein the contacting is for at least 2 hours.
11. 11. The method of any one of claims 1 to 10, wherein monocytes are pro-inflammatory before contact with the isolated MSC exosomes and are regulatory after contact with the isolated MSC exosomes.
12. 1. A method for treating a fibrotic disease, comprising administering an effective amount of monocytes to a subject in need thereof, wherein the monocytes are treated with isolated mesenchymal stem cell (MSC) exosomes prior to administration.
13. 1. A method for treating an autoimmune disease, comprising administering an effective amount of monocytes to a subject in need thereof, wherein the monocytes are treated with isolated mesenchymal stem cell (MSC) exosomes prior to administration.
14. 14. The method of claim 12 or claim 13, further comprising isolating monocytes prior to treating the monocytes with the MSC exosomes.
15. The method of claim 14, wherein the monocytes are isolated from the subject.
16. 16. The method of claim 15, wherein the monocytes are isolated from the subject's bone marrow.
17. The method of any one of claims 12 to 16, wherein the monocytes are treated with the MSC exosomes for at least 2 hours before being administered to the subject.
18. The method of any one of claims 12 to 17, wherein the monocytes are administered systemically.
19. 20. The method of claim 18, wherein the monocytes are administered via intravenous infusion.
20. The method of any one of claims 12 to 18, wherein the monocytes are administered intratracheally or intranasally.
21. The method of any one of claims 12 to 20, wherein the monocytes are administered once to the subject.
22. The method of any one of claims 12 to 21, wherein the monocytes are administered to the subject multiple times.
23. The method of any one of claims 12 to 22, further comprising administering to the subject an effective amount of a second agent.
24. 24. The method of claim 23, wherein the second agent is an isolated MCS exosome.
25. 24. The method of claim 23, wherein the second agent is nintedanib, pirfenidone, an anti-fibrotic agent, an immunosuppressant, and / or an anti-inflammatory agent.
26. The method of any one of claims 12 and 14 to 25, wherein the fibrotic disease is selected from the group consisting of: systemic sclerosis; liver fibrosis, cardiac fibrosis, renal fibrosis, and bone marrow fibrosis.
27. 27. The method of claim 26, wherein the fibrotic disease is pulmonary fibrosis.
28. 28. The method of claim 27, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).
29. The method of any one of claims 12 and 12 to 28, wherein the monocytes reduce inflammation associated with a fibrotic disease.
30. The method of any one of claims 12 and 12 to 29, wherein monocytes reduce apoptosis associated with fibrotic disease.
31. The method according to any one of claims 12 to 30, wherein the subject is a mammal.
32. 32. The method of claim 31 , wherein the subject is a human subject.
33. 33. The method of claim 32, wherein the human is a neonate, an infant, or an adult.
34. 33. The method of claim 32, wherein the human subject is less than 4 weeks of age.
35. 33. The method of claim 32, wherein the human subject is between 4 weeks and 3 years of age.
36. 33. The method of claim 32, wherein the human subject is between 3 and 18 years old.
37. 33. The method of claim 32, wherein the human subject is an adult.
38. The method of any one of claims 32 to 37, wherein the human subject is born with low birth weight.
39. 40. The method of claim 38, wherein the human subject was born before 37 weeks gestation.
40. 40. The method of claim 38, wherein the human subject was born before 26 weeks gestation.
41. 32. The method of claim 31 , wherein the subject is a rodent.
42. 42. The method of claim 41, wherein the rodent is a mouse or a rat.
43. The method of any one of claims 12 to 42, wherein monocytes are pro-inflammatory before being treated with the isolated MSC exosomes and are regulatory after being treated with the isolated MSC exosomes.
44. Monocytes treated with isolated mesenchymal stem cell (MSC) exosomes.
45. 45. The monocyte of claim 44, wherein the monocyte is from bone marrow.
46. The monocyte of claim 44 or claim 45, wherein the isolated MSC exosomes are isolated from MSC conditioned medium.
47. The monocyte of any one of claims 44 to 46, wherein the MSC is from Wharton's jelly or bone marrow or adipose tissue.
48. The monocytes of any one of claims 44 to 47, wherein the monocytes are pro-inflammatory before being treated with the isolated MSC exosomes and are regulatory after being treated with the isolated MSC exosomes.
49. A composition comprising monocytes according to any one of claims 42 to 48.
50. 50. The composition of claim 49, further comprising a second agent.
51. 51. The composition of claim 49 or claim 50, which is a pharmaceutical composition.
52. The composition of any one of claims 49 to 51, further comprising a pharma- ceutically acceptable carrier.
53. Use of monocytes according to any one of claims 44 to 48 or a composition according to any one of claims 49 to 52 for treating a fibrotic disease.
54. Monocytes according to any one of claims 44 to 48 or a composition according to any one of claims 49 to 52 for use in the manufacture of a medicament for treating a fibrotic disease.
55. Use of monocytes according to any one of claims 44 to 48 or a composition according to any one of claims 49 to 52 for treating an autoimmune disease.
56. Monocytes according to any one of claims 44 to 48 or a composition according to any one of claims 49 to 52 for use in the manufacture of a medicament for treating an autoimmune disease.
